

---

## ***7.BIBLIOGRAFIA***



1. Bosmans, J.M., Kockx, M.M., Vrints, C.J., Bult, H., De Meyer, G.R., and Herman, A.G., *Fibrin(ogen) and von Willebrand factor deposition are associated with intimal thickening after balloon angioplasty of the rabbit carotid artery*. *Arterioscler Thromb Vasc Biol*, 1997. 17(4): p. 634-45.
2. Sidawy, A., Sumpio, B., and De Palma, R., *The basic science of vascular disease*. 1997: Ed: Futura.
3. Lahera, V., Navarro-Cid, J., Cachofeiro, V., Garcia-Estan, J., and Ruilope, L.M., *Nitric oxide, the kidney, and hypertension*. *Am J Hypertens*, 1997. 10(1): p. 129-40.
4. Danese, S., Dejana, E., and Fiocchi, C., *Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation*. *J Immunol*, 2007. 178(10): p. 6017-22.
5. Iwasaki, A. and Medzhitov, R., *Toll-like receptor control of the adaptive immune responses*. *Nat Immunol*, 2004. 5(10): p. 987-95.
6. Heidemann, J., Domschke, W., Kucharzik, T., and Maaser, C., *Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: a second line of defense?* *Infect Immun*, 2006. 74(10): p. 5425-32.
7. Marelli-Berg, F.M. and Jarmin, S.J., *Antigen presentation by the endothelium: a green light for antigen-specific T cell trafficking?* *Immunol Lett*, 2004. 93(2-3): p. 109-13.
8. Dahlback, B. and Villoutreix, B.O., *Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition*. *Arterioscler Thromb Vasc Biol*, 2005. 25(7): p. 1311-20.
9. Carmeliet, P., *Mechanisms of angiogenesis and arteriogenesis*. *Nat Med*, 2000. 6(4): p. 389-95.
10. Carmeliet, P., *Angiogenesis in health and disease*. *Nat Med*, 2003. 9(6): p. 653-60.
11. Frantz, S., Vincent, K.A., Feron, O., and Kelly, R.A., *Innate immunity and angiogenesis*. *Circ Res*, 2005. 96(1): p. 15-26.
12. von Andrian, U.H. and Engelhardt, B., *Alpha4 integrins as therapeutic targets in autoimmune disease*. *N Engl J Med*, 2003. 348(1): p. 68-72.
13. Tedder, T.F., Steeber, D.A., Chen, A., and Engel, P., *The selectins: vascular adhesion molecules*. *Faseb J*, 1995. 9(10): p. 866-73.
14. Eppihimer, M.J., Wolitzky, B., Anderson, D.C., Labow, M.A., and Granger, D.N., *Heterogeneity of expression of E- and P-selectins in vivo*. *Circ Res*, 1996. 79(3): p. 560-9.
15. Cordell, J.L., Pulford, K., Turley, H., Jones, M., Micklem, K., Doussis, I.A., Tyler, X., Mayne, K., Gatter, K.C., and Mason, D.Y., *Cellular distribution of human leucocyte adhesion molecule ICAM-3*. *J Clin Pathol*, 1994. 47(2): p. 143-7.
16. Staunton, D.E., Dustin, M.L., and Springer, T.A., *Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1*. *Nature*, 1989. 339(6219): p. 61-4.
17. Elices, M.J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M.E., and Lobb, R.R., *VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site*. *Cell*, 1990. 60(4): p. 577-84.
18. Strauch, U.G., Lifka, A., Gossler, U., Kilshaw, P.J., Clements, J., and Holzmann, B., *Distinct binding specificities of integrins alpha 4 beta 7 (LPAM-1), alpha 4 beta 1 (VLA-4), and alpha IEL beta 7*. *Int Immunol*, 1994. 6(2): p. 263-75.
19. Wakelin, M.W., Sanz, M.J., Dewar, A., Albelda, S.M., Larkin, S.W., Boughton-Smith, N., Williams, T.J., and Nourshargh, S., *An anti-platelet-endothelial cell adhesion molecule-1 antibody inhibits leukocyte extravasation from mesenteric microvessels in vivo by blocking the passage through the basement membrane*. *J Exp Med*, 1996. 184(1): p. 229-39.

20. Streeter, P.R., Berg, E.L., Rouse, B.T., Bargatze, R.F., and Butcher, E.C., *A tissue-specific endothelial cell molecule involved in lymphocyte homing*. *Nature*, 1988. 331(6151): p. 41-6.
21. Read, M.A., Neish, A.S., Luscinskas, F.W., Palombella, V.J., Maniatis, T., and Collins, T., *The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression*. *Immunity*, 1995. 2(5): p. 493-506.
22. Weyrich, A.S. and Zimmerman, G.A., *Platelets: signaling cells in the immune continuum*. *Trends Immunol*, 2004. 25(9): p. 489-95.
23. Vlodavsky, I., Eldor, A., Haimovitz-Friedman, A., Matzner, Y., Ishai-Michaeli, R., Lider, O., Naparstek, Y., Cohen, I.R., and Fuks, Z., *Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation*. *Invasion Metastasis*, 1992. 12(2): p. 112-27.
24. Cooper, D., Stokes, K.Y., Tailor, A., and Granger, D.N., *Oxidative stress promotes blood cell-endothelial cell interactions in the microcirculation*. *Cardiovasc Toxicol*, 2002. 2(3): p. 165-80.
25. Stokes, K.Y., Clanton, E.C., Russell, J.M., Ross, C.R., and Granger, D.N., *NAD(P)H oxidase-derived superoxide mediates hypercholesterolemia-induced leukocyte-endothelial cell adhesion*. *Circ Res*, 2001. 88(5): p. 499-505.
26. Hickey, M.J. and Kubes, P., *Role of nitric oxide in regulation of leucocyte-endothelial cell interactions*. *Exp Physiol*, 1997. 82(2): p. 339-48.
27. Lefer, D.J., Jones, S.P., Girod, W.G., Baines, A., Grisham, M.B., Cockrell, A.S., Huang, P.L., and Scalia, R., *Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice*. *Am J Physiol*, 1999. 276(6 Pt 2): p. H1943-50.
28. Granger, D.N., Vowinkel, T., and Petnehazy, T., *Modulation of the inflammatory response in cardiovascular disease*. *Hypertension*, 2004. 43(5): p. 924-31.
29. Stokes, K.Y., Cooper, D., Tailor, A., and Granger, D.N., *Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide*. *Free Radic Biol Med*, 2002. 33(8): p. 1026-36.
30. Nickenig, G., *Central role of the AT(1)-receptor in atherosclerosis*. *J Hum Hypertens*, 2002. 16 Suppl 3: p. S26-33.
31. Cai, H., Griendling, K.K., and Harrison, D.G., *The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases*. *Trends Pharmacol Sci*, 2003. 24(9): p. 471-8.
32. Costanzo, A., Moretti, F., Burgio, V.L., Bravi, C., Guido, F., Levrero, M., and Puri, P.L., *Endothelial activation by angiotensin II through NFkappaB and p38 pathways: Involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin*. *J Cell Physiol*, 2003. 195(3): p. 402-10.
33. Phillips, M.I. and Kagiya, S., *Angiotensin II as a pro-inflammatory mediator*. *Curr Opin Investig Drugs*, 2002. 3(4): p. 569-77.
34. Nickenig, G. and Harrison, D.G., *The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis*. *Circulation*, 2002. 105(3): p. 393-6.
35. Alvarez, A. and Sanz, M.J., *Reactive oxygen species mediate angiotensin II-induced leukocyte-endothelial cell interactions in vivo*. *J Leukoc Biol*, 2001. 70(2): p. 199-206.
36. Locksley, R.M., Killeen, N., and Lenardo, M.J., *The TNF and TNF receptor superfamilies: integrating mammalian biology*. *Cell*, 2001. 104(4): p. 487-501.
37. van Kooten, C. and Banchereau, J., *CD40-CD40 ligand*. *J Leukoc Biol*, 2000. 67(1): p. 2-17.
38. Stamenkovic, I., Clark, E.A., and Seed, B., *A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas*. *Embo J*, 1989. 8(5): p. 1403-10.

39. Clark, E.A. and Ledbetter, J.A., *Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50*. Proc Natl Acad Sci U S A, 1986. 83(12): p. 4494-8.
40. Schonbeck, U. and Libby, P., *The CD40/CD154 receptor/ligand dyad*. Cell Mol Life Sci, 2001. 58(1): p. 4-43.
41. Wykes, M., Poudrier, J., Lindstedt, R., and Gray, D., *Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells*. Eur J Immunol, 1998. 28(2): p. 548-59.
42. Pietravalle, F., Lecoanet-Henchoz, S., Blasey, H., Aubry, J.P., Elson, G., Edgerton, M.D., Bonnefoy, J.Y., and Gauchat, J.F., *Human native soluble CD40L is a biologically active trimer, processed inside microsomes*. J Biol Chem, 1996. 271(11): p. 5965-7.
43. Pinchuk, L.M., Klaus, S.J., Magaletti, D.M., Pinchuk, G.V., Norsen, J.P., and Clark, E.A., *Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation*. J Immunol, 1996. 157(10): p. 4363-70.
44. Schonbeck, U. and Libby, P., *CD40 signaling and plaque instability*. Circ Res, 2001. 89(12): p. 1092-103.
45. Chan, F.K., Chun, H.J., Zheng, L., Siegel, R.M., Bui, K.L., and Lenardo, M.J., *A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling*. Science, 2000. 288(5475): p. 2351-4.
46. Ishida, T.K., Tojo, T., Aoki, T., Kobayashi, N., Ohishi, T., Watanabe, T., Yamamoto, T., and Inoue, J., *TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling*. Proc Natl Acad Sci U S A, 1996. 93(18): p. 9437-42.
47. Inoue, J., Ishida, T., Tsukamoto, N., Kobayashi, N., Naito, A., Azuma, S., and Yamamoto, T., *Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling*. Exp Cell Res, 2000. 254(1): p. 14-24.
48. Saitoh, M., Nishitoh, H., Fujii, M., Takeda, K., Tobiume, K., Sawada, Y., Kawabata, M., Miyazono, K., and Ichijo, H., *Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1*. Embo J, 1998. 17(9): p. 2596-606.
49. Wang, C., Deng, L., Hong, M., Akkaraju, G.R., Inoue, J., and Chen, Z.J., *TAK1 is a ubiquitin-dependent kinase of MKK and IKK*. Nature, 2001. 412(6844): p. 346-51.
50. Lee, N.K. and Lee, S.Y., *Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs)*. J Biochem Mol Biol, 2002. 35(1): p. 61-6.
51. Rothe, M., Xiong, J., Shu, H.B., Williamson, K., Goddard, A., and Goeddel, D.V., *I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction*. Proc Natl Acad Sci U S A, 1996. 93(16): p. 8241-6.
52. Nomura, F., Kawai, T., Nakanishi, K., and Akira, S., *NF-kappaB activation through IKK-i-dependent I-TRAF/TANK phosphorylation*. Genes Cells, 2000. 5(3): p. 191-202.
53. Jalukar, S.V., Hostager, B.S., and Bishop, G.A., *Characterization of the roles of TNF receptor-associated factor 6 in CD40-mediated B lymphocyte effector functions*. J Immunol, 2000. 164(2): p. 623-30.
54. Karras, J.G., Wang, Z., Huo, L., Frank, D.A., and Rothstein, T.L., *Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement*. J Immunol, 1997. 159(9): p. 4350-5.
55. Darnell, J.E., Jr., Kerr, I.M., and Stark, G.R., *Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins*. Science, 1994. 264(5164): p. 1415-21.
56. Uckun, F.M., Schieven, G.L., Dibirdik, I., Chandan-Langlie, M., Tuel-Ahlgren, L., and Ledbetter, J.A., *Stimulation of protein tyrosine phosphorylation, phosphoinositide turnover, and multiple previously unidentified serine/threonine-specific protein kinases*

- by the Pan-B-cell receptor CD40/Bp50 at discrete developmental stages of human B-cell ontogeny. *J Biol Chem*, 1991. 266(26): p. 17478-85.
57. Aagaard-Tillery, K.M. and Jelinek, D.F., *Phosphatidylinositol 3-kinase activation in normal human B lymphocytes*. *J Immunol*, 1996. 156(12): p. 4543-54.
  58. Tan, J., Town, T., and Mullan, M., *CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway*. *J Biol Chem*, 2000. 275(47): p. 37224-31.
  59. Suttles, J., Milhorn, D.M., Miller, R.W., Poe, J.C., Wahl, L.M., and Stout, R.D., *CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action*. *J Biol Chem*, 1999. 274(9): p. 5835-42.
  60. Jabara, H.H. and Geha, R.S., *Jun N-terminal kinase is essential for CD40-mediated IgE class switching in B cells*. *J Allergy Clin Immunol*, 2005. 115(4): p. 856-63.
  61. Francis, D.A., Karras, J.G., Ke, X.Y., Sen, R., and Rothstein, T.L., *Induction of the transcription factors NF-kappa B, AP-1 and NF-AT during B cell stimulation through the CD40 receptor*. *Int Immunol*, 1995. 7(2): p. 151-61.
  62. Yanagihara, Y., Basaki, Y., Ikizawa, K., and Kajiwara, K., *Possible role of nuclear factor-kappa B activity in germline C epsilon transcription in a human Burkitt lymphoma B cell line*. *Cell Immunol*, 1997. 176(1): p. 66-74.
  63. Huo, L. and Rothstein, T.L., *Receptor-specific induction of individual AP-1 components in B lymphocytes*. *J Immunol*, 1995. 154(7): p. 3300-9.
  64. Berberich, I., Shu, G., Siebelt, F., Woodgett, J.R., Kyriakis, J.M., and Clark, E.A., *Cross-linking CD40 on B cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases*. *Embo J*, 1996. 15(1): p. 92-101.
  65. Klaus, G.G., Choi, M.S., and Holman, M., *Properties of mouse CD40. Ligation of CD40 activates B cells via a Ca(++)-dependent, FK506-sensitive pathway*. *Eur J Immunol*, 1994. 24(12): p. 3229-32.
  66. Lam, E.W., Choi, M.S., van der Sman, J., Burbidge, S.A., and Klaus, G.G., *Modulation of E2F activity via signaling through surface IgM and CD40 receptors in WEHI-231 B lymphoma cells*. *J Biol Chem*, 1998. 273(16): p. 10051-7.
  67. Thanos, D. and Maniatis, T., *NF-kappa B: a lesson in family values*. *Cell*, 1995. 80(4): p. 529-32.
  68. Traenckner, E.B., Pahl, H.L., Henkel, T., Schmidt, K.N., Wilk, S., and Baeuerle, P.A., *Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli*. *Embo J*, 1995. 14(12): p. 2876-83.
  69. Traenckner, E.B., Wilk, S., and Baeuerle, P.A., *A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B*. *Embo J*, 1994. 13(22): p. 5433-41.
  70. Henkel, T., Machleidt, T., Alkalay, I., Kronke, M., Ben-Neriah, Y., and Baeuerle, P.A., *Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B*. *Nature*, 1993. 365(6442): p. 182-5.
  71. Regnier, C.H., Song, H.Y., Gao, X., Goeddel, D.V., Cao, Z., and Rothe, M., *Identification and characterization of an IkappaB kinase*. *Cell*, 1997. 90(2): p. 373-83.
  72. Harnett, M.M., *CD40: a growing cytoplasmic tale*. *Sci STKE*, 2004. 2004(237): p. pe25.
  73. Zirlik, A., Bavendiek, U., Libby, P., MacFarlane, L., Gerdes, N., Jagielska, J., Ernst, S., Aikawa, M., Nakano, H., Tsitsikov, E., and Schonbeck, U., *TRAF-1, -2, -3, -5, and -6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells*. *Arterioscler Thromb Vasc Biol*, 2007. 27(5): p. 1101-7.

74. Pearson, L.L., Castle, B.E., and Kehry, M.R., *CD40-mediated signaling in monocytic cells: up-regulation of tumor necrosis factor receptor-associated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways*. *Int Immunol*, 2001. 13(3): p. 273-83.
75. Schwenzer, R., Sieminski, K., Liptay, S., Schubert, G., Peters, N., Scheurich, P., Schmid, R.M., and Wajant, H., *The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappaB and c-Jun N-terminal kinase*. *J Biol Chem*, 1999. 274(27): p. 19368-74.
76. Song, H.Y., Regnier, C.H., Kirschning, C.J., Goeddel, D.V., and Rothe, M., *Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2*. *Proc Natl Acad Sci U S A*, 1997. 94(18): p. 9792-6.
77. Tada, K., Okazaki, T., Sakon, S., Kobarai, T., Kurosawa, K., Yamaoka, S., Hashimoto, H., Mak, T.W., Yagita, H., Okumura, K., Yeh, W.C., and Nakano, H., *Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death*. *J Biol Chem*, 2001. 276(39): p. 36530-4.
78. Andrade, R.M., Wessendarp, M., Portillo, J.A., Yang, J.Q., Gomez, F.J., Durbin, J.E., Bishop, G.A., and Subauste, C.S., *TNF receptor-associated factor 6-dependent CD40 signaling primes macrophages to acquire antimicrobial activity in response to TNF-alpha*. *J Immunol*, 2005. 175(9): p. 6014-21.
79. Mukundan, L., Bishop, G.A., Head, K.Z., Zhang, L., Wahl, L.M., and Suttles, J., *TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages*. *J Immunol*, 2005. 174(2): p. 1081-90.
80. Lomaga, M.A., Yeh, W.C., Sarosi, I., Duncan, G.S., Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G., Kaufman, S., van der Heiden, A., Itie, A., Wakeham, A., Khoo, W., Sasaki, T., Cao, Z., Penninger, J.M., Paige, C.J., Lacey, D.L., Dunstan, C.R., Boyle, W.J., Goeddel, D.V., and Mak, T.W., *TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling*. *Genes Dev*, 1999. 13(8): p. 1015-24.
81. Mukundan, L., Milhorn, D.M., Matta, B., and Suttles, J., *CD40-mediated activation of vascular smooth muscle cell chemokine production through a Src-initiated, MAPK-dependent pathway*. *Cell Signal*, 2004. 16(3): p. 375-84.
82. Karmann, K., Min, W., Fanslow, W.C., and Pober, J.S., *Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1*. *J Exp Med*, 1996. 184(1): p. 173-82.
83. Foy, T.M., Aruffo, A., Bajorath, J., Buhlmann, J.E., and Noelle, R.J., *Immune regulation by CD40 and its ligand GP39*. *Annu Rev Immunol*, 1996. 14: p. 591-617.
84. Grewal, I.S. and Flavell, R.A., *CD40 and CD154 in cell-mediated immunity*. *Annu Rev Immunol*, 1998. 16: p. 111-35.
85. Mackey, M.F., Barth, R.J., Jr., and Noelle, R.J., *The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells*. *J Leukoc Biol*, 1998. 63(4): p. 418-28.
86. Lenschow, D.J., Su, G.H., Zuckerman, L.A., Nabavi, N., Jellis, C.L., Gray, G.S., Miller, J., and Bluestone, J.A., *Expression and functional significance of an additional ligand for CTLA-4*. *Proc Natl Acad Sci U S A*, 1993. 90(23): p. 11054-8.
87. Krensky, A.M., Weiss, A., Crabtree, G., Davis, M.M., and Parham, P., *T-lymphocyte-antigen interactions in transplant rejection*. *N Engl J Med*, 1990. 322(8): p. 510-7.
88. Sayegh, M.H., *Finally, CTLA4Ig graduates to the clinic*. *J Clin Invest*, 1999. 103(9): p. 1223-5.

89. Van Gool, S.W., Vandenberghe, P., de Boer, M., and Ceuppens, J.L., *CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model*. Immunol Rev, 1996. 153: p. 47-83.
90. Sartor, R.B., *Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases*. Am J Gastroenterol, 1997. 92(12 Suppl): p. 5S-11S.
91. Bieber, T., de la Salle, H., Wollenberg, A., Hakimi, J., Chizzonite, R., Ring, J., Hanau, D., and de la Salle, C., *Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI)*. J Exp Med, 1992. 175(5): p. 1285-90.
92. Castigli, E., Alt, F.W., Davidson, L., Bottaro, A., Mizoguchi, E., Bhan, A.K., and Geha, R.S., *CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation*. Proc Natl Acad Sci U S A, 1994. 91(25): p. 12135-9.
93. Kawabe, T., Naka, T., Yoshida, K., Tanaka, T., Fujiwara, H., Suematsu, S., Yoshida, N., Kishimoto, T., and Kikutani, H., *The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation*. Immunity, 1994. 1(3): p. 167-78.
94. Dubois, B., Massacrier, C., Vanbervliet, B., Fayette, J., Briere, F., Banchereau, J., and Caux, C., *Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes*. J Immunol, 1998. 161(5): p. 2223-31.
95. Lu, L., Bonham, C.A., Chambers, F.G., Watkins, S.C., Hoffman, R.A., Simmons, R.L., and Thomson, A.W., *Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis*. J Immunol, 1996. 157(8): p. 3577-86.
96. Stout, R.D., Suttles, J., Xu, J., Grewal, I.S., and Flavell, R.A., *Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice*. J Immunol, 1996. 156(1): p. 8-11.
97. Hollenbaugh, D., Mischel-Petty, N., Edwards, C.P., Simon, J.C., Denfeld, R.W., Kiener, P.A., and Aruffo, A., *Expression of functional CD40 by vascular endothelial cells*. J Exp Med, 1995. 182(1): p. 33-40.
98. Yellin, M.J., Brett, J., Baum, D., Matsushima, A., Szabolcs, M., Stern, D., and Chess, L., *Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals*. J Exp Med, 1995. 182(6): p. 1857-64.
99. Karmann, K., Hughes, C.C., Schechner, J., Fanslow, W.C., and Pober, J.S., *CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression*. Proc Natl Acad Sci U S A, 1995. 92(10): p. 4342-6.
100. Pammer, J., Plettenberg, A., Weninger, W., Diller, B., Mildner, M., Uthman, A., Issing, W., Sturzl, M., and Tschachler, E., *CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma*. Am J Pathol, 1996. 148(5): p. 1387-96.
101. Kluth, B., Hess, S., Engelmann, H., Schafnitzel, S., Riethmuller, G., and Feucht, H.E., *Endothelial expression of CD40 in renal cell carcinoma*. Cancer Res, 1997. 57(5): p. 891-9.
102. Mach, F., Schonbeck, U., Sukhova, G.K., Bourcier, T., Bonnefoy, J.Y., Pober, J.S., and Libby, P., *Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis*. Proc Natl Acad Sci U S A, 1997. 94(5): p. 1931-6.
103. Mach, F., Schonbeck, U., Sukhova, G.K., Atkinson, E., and Libby, P., *Reduction of atherosclerosis in mice by inhibition of CD40 signalling*. Nature, 1998. 394(6689): p. 200-3.
104. Yellin, M.J., D'Agati, V., Parkinson, G., Han, A.S., Szema, A., Baum, D., Estes, D., Szabolcs, M., and Chess, L., *Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides*. Arthritis Rheum, 1997. 40(1): p. 124-34.



105. Moses, A.V., Williams, S.E., Strussenberg, J.G., Heneveld, M.L., Ruhl, R.A., Bakke, A.C., Bagby, G.C., and Nelson, J.A., *HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas*. *Nat Med*, 1997. 3(11): p. 1242-9.
106. Suo, Z., Tan, J., Placzek, A., Crawford, F., Fang, C., and Mullan, M., *Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40*. *Brain Res*, 1998. 807(1-2): p. 110-7.
107. Reul, R.M., Fang, J.C., Denton, M.D., Geehan, C., Long, C., Mitchell, R.N., Ganz, P., and Briscoe, D.M., *CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection*. *Transplantation*, 1997. 64(12): p. 1765-74.
108. Otterdal, K., Pedersen, T.M., and Solum, N.O., *Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase*. *Thromb Res*, 2004. 114(3): p. 167-77.
109. Viallard, J.F., Solanilla, A., Gauthier, B., Contin, C., Dechanet, J., Grosset, C., Moreau, J.F., Praloran, V., Nurden, P., Pellegrin, J.L., Nurden, A.T., and Ripoche, J., *Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis*. *Blood*, 2002. 99(7): p. 2612-4.
110. Lindmark, E., Tenno, T., and Siegbahn, A., *Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression*. *Arterioscler Thromb Vasc Biol*, 2000. 20(10): p. 2322-8.
111. May, A.E., Kalsch, T., Massberg, S., Herouy, Y., Schmidt, R., and Gawaz, M., *Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells*. *Circulation*, 2002. 106(16): p. 2111-7.
112. Ross, R., *Atherosclerosis--an inflammatory disease*. *N Engl J Med*, 1999. 340(2): p. 115-26.
113. Libby, P., Ridker, P.M., and Maseri, A., *Inflammation and atherosclerosis*. *Circulation*, 2002. 105(9): p. 1135-43.
114. Luscher, T.F. and Noll, G., *Endothelial function as an end-point in interventional trials: concepts, methods and current data*. *J Hypertens Suppl*, 1996. 14(2): p. S111-9; discussion S119-21.
115. Farb, A., Burke, A.P., Tang, A.L., Liang, T.Y., Mannan, P., Smialek, J., and Virmani, R., *Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death*. *Circulation*, 1996. 93(7): p. 1354-63.
116. Dimmeler, S., Hermann, C., and Zeiher, A.M., *Apoptosis of endothelial cells. Contribution to the pathophysiology of atherosclerosis?* *Eur Cytokine Netw*, 1998. 9(4): p. 697-8.
117. Urbich, C., Dernbach, E., Aicher, A., Zeiher, A.M., and Dimmeler, S., *CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species*. *Circulation*, 2002. 106(8): p. 981-6.
118. Tricot, O., Mallat, Z., Heymes, C., Belmin, J., Leseche, G., and Tedgui, A., *Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques*. *Circulation*, 2000. 101(21): p. 2450-3.
119. Urbich, C., Mallat, Z., Tedgui, A., Clauss, M., Zeiher, A.M., and Dimmeler, S., *Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation*. *J Clin Invest*, 2001. 108(10): p. 1451-8.
120. Schonbeck, U., Sukhova, G.K., Shimizu, K., Mach, F., and Libby, P., *Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice*. *Proc Natl Acad Sci U S A*, 2000. 97(13): p. 7458-63.
121. Cai, H. and Harrison, D.G., *Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress*. *Circ Res*, 2000. 87(10): p. 840-4.

122. Nickenig, G. and Harrison, D.G., *The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation*. *Circulation*, 2002. 105(4): p. 530-6.
123. Garlich, C.D., John, S., Schmeisser, A., Eskafi, S., Stumpf, C., Karl, M., Goppelt-Struebe, M., Schmieder, R., and Daniel, W.G., *Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia*. *Circulation*, 2001. 104(20): p. 2395-400.
124. Aukrust, P., Muller, F., Ueland, T., Berget, T., Aaser, E., Brunsvig, A., Solum, N.O., Forfang, K., Froland, S.S., and Gullestad, L., *Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes*. *Circulation*, 1999. 100(6): p. 614-20.
125. Yndestad, A., Damas, J.K., Geir Eiken, H., Holm, T., Haug, T., Simonsen, S., Froland, S.S., Gullestad, L., and Aukrust, P., *Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure*. *Cardiovasc Res*, 2002. 54(1): p. 175-82.
126. Schonbeck, U., Varo, N., Libby, P., Buring, J., and Ridker, P.M., *Soluble CD40L and cardiovascular risk in women*. *Circulation*, 2001. 104(19): p. 2266-8.
127. Heeschen, C., Dimmeler, S., Hamm, C.W., van den Brand, M.J., Boersma, E., Zeiher, A.M., and Simoons, M.L., *Soluble CD40 ligand in acute coronary syndromes*. *N Engl J Med*, 2003. 348(12): p. 1104-11.
128. Blake, G.J., Ostfeld, R.J., Yucel, E.K., Varo, N., Schonbeck, U., Blake, M.A., Gerhard, M., Ridker, P.M., Libby, P., and Lee, R.T., *Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI*. *Arterioscler Thromb Vasc Biol*, 2003. 23(1): p. e11-4.
129. Schonbeck, U., Gerdes, N., Varo, N., Reynolds, R.S., Horton, D.B., Bavendiek, U., Robbie, L., Ganz, P., Kinlay, S., and Libby, P., *Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells*. *Circulation*, 2002. 106(23): p. 2888-93.
130. Wagner, A.H., Gebauer, M., Guldenzoph, B., and Hecker, M., *3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells*. *Arterioscler Thromb Vasc Biol*, 2002. 22(11): p. 1784-9.
131. Semb, A.G., van Wissen, S., Ueland, T., Smilde, T., Waehre, T., Tripp, M.D., Froland, S.S., Kastelein, J.J., Gullestad, L., Pedersen, T.R., Aukrust, P., and Stalenhoef, A.F., *Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy*. *J Am Coll Cardiol*, 2003. 41(2): p. 275-9.
132. Nannizzi-Alaimo, L., Alves, V.L., and Phillips, D.R., *Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation*. *Circulation*, 2003. 107(8): p. 1123-8.
133. Ma, J., Xu, J., Madaio, M.P., Peng, Q., Zhang, J., Grewal, I.S., Flavell, R.A., and Craft, J., *Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses*. *J Immunol*, 1996. 157(1): p. 417-26.
134. Durie, F.H., Fava, R.A., and Noelle, R.J., *Collagen-induced arthritis as a model of rheumatoid arthritis*. *Clin Immunol Immunopathol*, 1994. 73(1): p. 11-8.
135. Grewal, I.S., Foellmer, H.G., Grewal, K.D., Xu, J., Hardardottir, F., Baron, J.L., Janeway, C.A., Jr., and Flavell, R.A., *Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis*. *Science*, 1996. 273(5283): p. 1864-7.

136. Samoiloova, E.B., Horton, J.L., Zhang, H., and Chen, Y., *CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation*. *J Mol Med*, 1997. 75(8): p. 603-8.
137. Laman, J.D., Maassen, C.B., Schellekens, M.M., Visser, L., Kap, M., de Jong, E., van Puijenbroek, M., van Stipdonk, M.J., van Meurs, M., Schwarzler, C., and Gunthert, U., *Therapy with antibodies against CD40L (CD154) and CD44-variant isoforms reduces experimental autoimmune encephalomyelitis induced by a proteolipid protein peptide*. *Mult Scler*, 1998. 4(3): p. 147-53.
138. Early, G.S., Zhao, W., and Burns, C.M., *Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response*. *J Immunol*, 1996. 157(7): p. 3159-64.
139. Van Doornum, S., McColl, G., and Wicks, I.P., *Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?* *Arthritis Rheum*, 2002. 46(4): p. 862-73.
140. Muller-Ladner, U. and Gay, S., *MMPs and rheumatoid synovial fibroblasts: Siamese twins in joint destruction?* *Ann Rheum Dis*, 2002. 61(11): p. 957-9.
141. Paleolog, E.M., *Angiogenesis in rheumatoid arthritis*. *Arthritis Res*, 2002. 4 Suppl 3: p. S81-90.
142. Salvi, R., Peclat, V., So, A., and Busso, N., *Enhanced expression of genes involved in coagulation and fibrinolysis in murine arthritis*. *Arthritis Res*, 2000. 2(6): p. 504-12.
143. Durie, F.H., Fava, R.A., Foy, T.M., Aruffo, A., Ledbetter, J.A., and Noelle, R.J., *Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40*. *Science*, 1993. 261(5126): p. 1328-30.
144. Morris, P.J., *Transplantation in the 21st century*. *Kidney Int Suppl*, 1997. 58: p. S51-5.
145. Halloran, P.F., *Immunosuppressive drugs for kidney transplantation*. *N Engl J Med*, 2004. 351(26): p. 2715-29.
146. Denton, M.D., Reul, R.M., Dharnidharka, V.R., Fang, J.C., Ganz, P., and Briscoe, D.M., *Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection*. *Pediatr Transplant*, 1998. 2(1): p. 6-15.
147. Gaweco, A.S., Mitchell, B.L., Lucas, B.A., McClatchey, K.D., and Van Thiel, D.H., *CD40 expression on graft infiltrates and parenchymal CD154 (CD40L) induction in human chronic renal allograft rejection*. *Kidney Int*, 1999. 55(4): p. 1543-52.
148. Zheng, X.X., Schachter, A.D., Vasconcellos, L., Strehlau, J., Tian, Y., Shapiro, M., Harmon, W., and Strom, T.B., *Increased CD40 ligand gene expression during human renal and murine islet allograft rejection*. *Transplantation*, 1998. 65(11): p. 1512-5.
149. Pearson, T.C., Alexander, D.Z., Corbascio, M., Hendrix, R., Ritchie, S.C., Linsley, P.S., Faherty, D., and Larsen, C.P., *Analysis of the B7 costimulatory pathway in allograft rejection*. *Transplantation*, 1997. 63(10): p. 1463-9.
150. Sayegh, M.H., Akalin, E., Hancock, W.W., Russell, M.E., Carpenter, C.B., Linsley, P.S., and Turka, L.A., *CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2*. *J Exp Med*, 1995. 181(5): p. 1869-74.
151. Haspot, F., Seveno, C., Dugast, A.S., Coulon, F., Renaudin, K., Usal, C., Hill, M., Anegon, I., Heslan, M., Josien, R., Brouard, S., Soulillou, J.P., and Vanhove, B., *Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells*. *Am J Transplant*, 2005. 5(10): p. 2339-48.
152. Laskowski, I.A., Pratschke, J., Wilhelm, M.J., Dong, V.M., Beato, F., Taal, M., Gasser, M., Hancock, W.W., Sayegh, M.H., and Tilney, N.L., *Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats*. *J Am Soc Nephrol*, 2002. 13(2): p. 519-27.
153. Janeway, C.A., Jr. and Bottomly, K., *Signals and signs for lymphocyte responses*. *Cell*, 1994. 76(2): p. 275-85.

154. Pearson, T.C., Alexander, D.Z., Winn, K.J., Linsley, P.S., Lowry, R.P., and Larsen, C.P., *Transplantation tolerance induced by CTLA4-Ig*. *Transplantation*, 1994. 57(12): p. 1701-6.
155. Schaub, M., Stadlbauer, T.H., and Sayegh, M.H., *CTLA4Ig: effects on cellular and humoral immunity and macrophage activation*. *Exp Nephrol*, 1997. 5(5): p. 370-4.
156. Azuma, H., Chandraker, A., Nadeau, K., Hancock, W.W., Carpenter, C.B., Tilney, N.L., and Sayegh, M.H., *Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection*. *Proc Natl Acad Sci U S A*, 1996. 93(22): p. 12439-44.
157. Chandraker, A., Azuma, H., Nadeau, K., Carpenter, C.B., Tilney, N.L., Hancock, W.W., and Sayegh, M.H., *Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection*. *J Clin Invest*, 1998. 101(11): p. 2309-18.
158. Kirk, A.D., Tadaki, D.K., Celniker, A., Batty, D.S., Berning, J.D., Colonna, J.O., Cruzata, F., Elster, E.A., Gray, G.S., Kampen, R.L., Patterson, N.B., Szklut, P., Swanson, J., Xu, H., and Harlan, D.M., *Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates*. *Transplantation*, 2001. 72(3): p. 377-84.
159. Montgomery, S.P., Xu, H., Tadaki, D.K., Celniker, A., Burkly, L.C., Berning, J.D., Cruzata, F., Elster, E.A., Gray, G., Kampen, R.L., Swanson, S.J., Harlan, D.M., and Kirk, A.D., *Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation*. *Transplantation*, 2002. 74(10): p. 1365-9.
160. Haanstra, K.G., Ringers, J., Sick, E.A., Ramdien-Murli, S., Kuhn, E.M., Boon, L., and Jonker, M., *Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates*. *Transplantation*, 2003. 75(5): p. 637-43.
161. Birsan, T., Hausen, B., Higgins, J.P., Hubble, R.W., Klupp, J., Stalder, M., Celniker, A., Friedrich, S., O'Hara, R.M., and Morris, R.E., *Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys*. *Transplantation*, 2003. 75(12): p. 2106-13.
162. Hausen, B., Klupp, J., Christians, U., Higgins, J.P., Baumgartner, R.E., Hook, L.E., Friedrich, S., Celnicker, A., and Morris, R.E., *Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys*. *Transplantation*, 2001. 72(6): p. 1128-37.
163. Ossevoort, M.A., Lorre, K., Boon, L., van den Hout, Y., de Boer, M., De Waele, P., Jonker, M., and VandeVoorde, A., *Prolonged skin graft survival by administration of anti-CD80 monoclonal antibody with cyclosporin A*. *J Immunother*, 1999. 22(5): p. 381-9.
164. Ossevoort, M.A., Ringers, J., Kuhn, E.M., Boon, L., Lorre, K., van den Hout, Y., Bruijn, J.A., de Boer, M., Jonker, M., and de Waele, P., *Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway*. *Transplantation*, 1999. 68(7): p. 1010-8.
165. Levisetti, M.G., Padrid, P.A., Szot, G.L., Mittal, N., Meehan, S.M., Wardrip, C.L., Gray, G.S., Bruce, D.S., Thistlethwaite, J.R., Jr., and Bluestone, J.A., *Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation*. *J Immunol*, 1997. 159(11): p. 5187-91.
166. Kirk, A.D., Harlan, D.M., Armstrong, N.N., Davis, T.A., Dong, Y., Gray, G.S., Hong, X., Thomas, D., Fechner, J.H., Jr., and Knechtle, S.J., *CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates*. *Proc Natl Acad Sci U S A*, 1997. 94(16): p. 8789-94.
167. Larsen, C.P., Pearson, T.C., Adams, A.B., Tso, P., Shirasugi, N., Strobertm, E., Anderson, D., Cowan, S., Price, K., Naemura, J., Emswiler, J., Greene, J., Turk, L.A.,

- Bajorath, J., Townsend, R., Hagerty, D., Linsley, P.S., and Peach, R.J., *Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties*. Am J Transplant, 2005. 5(3): p. 443-53.
168. Adams, A.B., Shirasugi, N., Durham, M.M., Strobert, E., Anderson, D., Rees, P., Cowan, S., Xu, H., Blinder, Y., Cheung, M., Hollenbaugh, D., Kenyon, N.S., Pearson, T.C., and Larsen, C.P., *Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates*. Diabetes, 2002. 51(2): p. 265-70.
169. Vincenti, F., Larsen, C., Durrbach, A., Wekerle, T., Nashan, B., Blancho, G., Lang, P., Grinyo, J., Halloran, P.F., Solez, K., Hagerty, D., Levy, E., Zhou, W., Natarajan, K., and Charpentier, B., *Costimulation blockade with belatacept in renal transplantation*. N Engl J Med, 2005. 353(8): p. 770-81.
170. Kirk, A.D., Burkly, L.C., Batty, D.S., Baumgartner, R.E., Berning, J.D., Buchanan, K., Fechner, J.H., Jr., Germond, R.L., Kampen, R.L., Patterson, N.B., Swanson, S.J., Tadaki, D.K., TenHoor, C.N., White, L., Knechtle, S.J., and Harlan, D.M., *Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates*. Nat Med, 1999. 5(6): p. 686-93.
171. Kenyon, N.S., Chatzipetrou, M., Masetti, M., Ranuncoli, A., Oliveira, M., Wagner, J.L., Kirk, A.D., Harlan, D.M., Burkly, L.C., and Ricordi, C., *Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154*. Proc Natl Acad Sci U S A, 1999. 96(14): p. 8132-7.
172. Parker, D.C., Greiner, D.L., Phillips, N.E., Appel, M.C., Steele, A.W., Durie, F.H., Noelle, R.J., Mordes, J.P., and Rossini, A.A., *Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand*. Proc Natl Acad Sci U S A, 1995. 92(21): p. 9560-4.
173. Pierson, R.N., 3rd, Crowe, J.E., Jr., Pfeiffer, S., Atkinson, J., Azimzadeh, A., and Miller, G.G., *CD40-ligand in primate cardiac allograft and viral immunity*. Immunol Res, 2001. 23(2-3): p. 253-62.
174. Pfeiffer, S., Iii, G.L., Azimzadeh, A.M., Atkinson, J., Newman, R., and Pierson, R.N., *Monotherapy with anti-CD40 ligand antibody (IDEC 131) for non-human primate allograft heart transplantation*. J Heart Lung Transplant, 2001. 20(2): p. 250.
175. Xu, H., Tadaki, D.K., Elster, E.A., Burkly, L.C., Berning, J.D., Cruzata, F., Kampen, R.L., Montgomery, S.P., Patterson, N.B., Harlan, D.M., and Kirk, A.D., *Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates*. Transplantation, 2002. 74(7): p. 940-3.
176. Elster, E.A., Xu, H., Tadaki, D.K., Burkly, L.C., Berning, J.D., Baumgartner, R.E., Cruzata, F., Patterson, N.B., Harlan, D.M., and Kirk, A.D., *Primate skin allotransplantation with anti-CD154 monotherapy*. Transplant Proc, 2001. 33(1-2): p. 675-6.
177. Kanmaz, T., Fechner, J.J., Jr., Torrealba, J., Kim, H.T., Dong, Y., Oberley, T.D., Schultz, J.M., Bloom, D.D., Katayama, M., Dar, W., Markovits, J., Schuler, W., Hu, H., Hamawy, M.M., and Knechtle, S.J., *Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model*. Transplantation, 2004. 77(6): p. 914-20.
178. Schuler, W., Bigaud, M., Brinkmann, V., Di Padova, F., Geisse, S., Gram, H., Hungerford, V., Kleuser, B., Kristofic, C., Menninger, K., Tees, R., Wiczorek, G., Wilt, C., Wioland, C., and Zurini, M., *Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation*. Transplantation, 2004. 77(5): p. 717-26.
179. Knosalla, C., Gollackner, B., and Cooper, D.K., *Anti-CD154 monoclonal antibody and thromboembolism revisited*. Transplantation, 2002. 74(3): p. 416-7.

180. Kawai, T., Andrews, D., Colvin, R.B., Sachs, D.H., and Cosimi, A.B., *Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand*. *Nat Med*, 2000. 6(2): p. 114.
181. Buhler, L., Alwayn, I.P., Appel, J.Z., 3rd, Robson, S.C., and Cooper, D.K., *Anti-CD154 monoclonal antibody and thromboembolism*. *Transplantation*, 2001. 71(3): p. 491.
182. Xu, H., Montgomery, S.P., Preston, E.H., Tadaki, D.K., Hale, D.A., Harlan, D.M., and Kirk, A.D., *Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation*. *J Immunol*, 2003. 170(5): p. 2776-82.
183. Preston, E.H., Xu, H., Dhanireddy, K.K., Pearl, J.P., Leopardi, F.V., Starost, M.F., Hale, D.A., and Kirk, A.D., *IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates*. *Am J Transplant*, 2005. 5(5): p. 1032-41.
184. Prasad, K.S., Andre, P., Yan, Y., and Phillips, D.R., *The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease*. *Curr Opin Hematol*, 2003. 10(5): p. 356-61.
185. Koyama, I., Kawai, T., Andrews, D., Boskovic, S., Nadazdin, O., Wee, S.L., Sogawa, H., Wu, D.L., Smith, R.N., Colvin, R.B., Sachs, D.H., and Cosimi, A.B., *Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates*. *Transplantation*, 2004. 77(3): p. 460-2.
186. Andre, P., Prasad, K.S., Denis, C.V., He, M., Papalia, J.M., Hynes, R.O., Phillips, D.R., and Wagner, D.D., *CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism*. *Nat Med*, 2002. 8(3): p. 247-52.
187. Ossevoort, M.A., Ringers, J., Boon, L., Lorre, K., van den Hout, Y., Kuhn, E.M., de Boer, M., Jonker, M., and de Waele, P., *Blocking of costimulation prevents kidney graft rejection in rhesus monkeys*. *Transplant Proc*, 1998. 30(5): p. 2165-6.
188. de Vos, A.F., Melief, M.J., van Riel, D., Boon, L., van Eijk, M., de Boer, M., and Laman, J.D., *Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys*. *Eur J Immunol*, 2004. 34(12): p. 3446-55.
189. Pearson, T.C., Trambley, J., Odom, K., Anderson, D.C., Cowan, S., Bray, R., Lin, A., Hollenbaugh, D., Aruffo, A., Siadak, A.W., Strobert, E., Hennigar, R., and Larsen, C.P., *Anti-CD40 therapy extends renal allograft survival in rhesus macaques*. *Transplantation*, 2002. 74(7): p. 933-40.
190. Adams, A.B., Shirasugi, N., Jones, T.R., Durham, M.M., Strobert, E.A., Cowan, S., Rees, P., Hendrix, R., Price, K., Kenyon, N.S., Hagerty, D., Townsend, R., Hollenbaugh, D., Pearson, T.C., and Larsen, C.P., *Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival*. *J Immunol*, 2005. 174(1): p. 542-50.
191. Haanstra, K.G., Sick, E.A., Ringers, J., Wubben, J.A., Kuhn, E.M., Boon, L., and Jonker, M., *Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts*. *Transplantation*, 2005. 79(11): p. 1623-6.
192. Li, Y., Li, X.C., Zheng, X.X., Wells, A.D., Turka, L.A., and Strom, T.B., *Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance*. *Nat Med*, 1999. 5(11): p. 1298-302.
193. Elwood, E.T., Larsen, C.P., Cho, H.R., Corbascio, M., Ritchie, S.C., Alexander, D.Z., Tucker-Burden, C., Linsley, P.S., Aruffo, A., Hollenbaugh, D., Winn, K.J., and Pearson, T.C., *Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade*. *Transplantation*, 1998. 65(11): p. 1422-8.
194. Elster, E.A., Xu, H., Tadaki, D.K., Montgomery, S., Burkly, L.C., Berning, J.D., Baumgartner, R.E., Cruzata, F., Marx, R., Harlan, D.M., and Kirk, A.D., *Treatment with*

- the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates.* Transplantation, 2001. 72(9): p. 1473-8.
195. Kean, L.S., Gangappa, S., Pearson, T.C., and Larsen, C.P., *Transplant tolerance in non-human primates: progress, current challenges and unmet needs.* Am J Transplant, 2006. 6(5 Pt 1): p. 884-93.
196. Dallas, A. and Vlassov, A.V., *RNAi: a novel antisense technology and its therapeutic potential.* Med Sci Monit, 2006. 12(4): p. RA67-74.
197. Stephenson, M.L. and Zamecnik, P.C., *Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.* Proc Natl Acad Sci U S A, 1978. 75(1): p. 285-8.
198. Crooke, S.T., *Progress in antisense technology.* Annu Rev Med, 2004. 55: p. 61-95.
199. Baker, B.F., Lot, S.S., Condon, T.P., Cheng-Flournoy, S., Lesnik, E.A., Sasmor, H.M., and Bennett, C.F., *2'-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells.* J Biol Chem, 1997. 272(18): p. 11994-2000.
200. Lu, Q.L., Mann, C.J., Lou, F., Bou-Gharios, G., Morris, G.E., Xue, S.A., Fletcher, S., Partridge, T.A., and Wilton, S.D., *Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.* Nat Med, 2003. 9(8): p. 1009-14.
201. Scherer, L.J. and Rossi, J.J., *Approaches for the sequence-specific knockdown of mRNA.* Nat Biotechnol, 2003. 21(12): p. 1457-65.
202. Jorgensen, R., *Altered gene expression in plants due to trans interactions between homologous genes.* Trends Biotechnol, 1990. 8(12): p. 340-4.
203. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C., *Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.* Nature, 1998. 391(6669): p. 806-11.
204. Ruiz, M.T., Voinnet, O., and Baulcombe, D.C., *Initiation and maintenance of virus-induced gene silencing.* Plant Cell, 1998. 10(6): p. 937-46.
205. Zamore, P.D., *RNA interference: listening to the sound of silence.* Nat Struct Biol, 2001. 8(9): p. 746-50.
206. Hammond, S.M., Caudy, A.A., and Hannon, G.J., *Post-transcriptional gene silencing by double-stranded RNA.* Nat Rev Genet, 2001. 2(2): p. 110-9.
207. Guo, S. and Kemphues, K.J., *par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed.* Cell, 1995. 81(4): p. 611-20.
208. Wargelius, A., Ellingsen, S., and Fjose, A., *Double-stranded RNA induces specific developmental defects in zebrafish embryos.* Biochem Biophys Res Commun, 1999. 263(1): p. 156-61.
209. Sanchez Alvarado, A. and Newmark, P.A., *Double-stranded RNA specifically disrupts gene expression during planarian regeneration.* Proc Natl Acad Sci U S A, 1999. 96(9): p. 5049-54.
210. Lohmann, J.U., Endl, I., and Bosch, T.C., *Silencing of developmental genes in Hydra.* Dev Biol, 1999. 214(1): p. 211-4.
211. Romano, N. and Macino, G., *Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences.* Mol Microbiol, 1992. 6(22): p. 3343-53.
212. Misquitta, L. and Paterson, B.M., *Targeted disruption of gene function in Drosophila by RNA interference (RNA-i): a role for nautilus in embryonic somatic muscle formation.* Proc Natl Acad Sci U S A, 1999. 96(4): p. 1451-6.

213. Wianny, F. and Zernicka-Goetz, M., *Specific interference with gene function by double-stranded RNA in early mouse development*. Nat Cell Biol, 2000. 2(2): p. 70-5.
214. Bartel, D.P., *MicroRNAs: genomics, biogenesis, mechanism, and function*. Cell, 2004. 116(2): p. 281-97.
215. Volpe, T.A., Kidner, C., Hall, I.M., Teng, G., Grewal, S.I., and Martienssen, R.A., *Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi*. Science, 2002. 297(5588): p. 1833-7.
216. Elbashir, S.M., Lendeckel, W., and Tuschl, T., *RNA interference is mediated by 21- and 22-nucleotide RNAs*. Genes Dev, 2001. 15(2): p. 188-200.
217. Bernstein, E., Caudy, A.A., Hammond, S.M., and Hannon, G.J., *Role for a bidentate ribonuclease in the initiation step of RNA interference*. Nature, 2001. 409(6818): p. 363-6.
218. Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W., and Tuschl, T., *Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate*. Embo J, 2001. 20(23): p. 6877-88.
219. Zhang, H., Kolb, F.A., Brondani, V., Billy, E., and Filipowicz, W., *Human Dicer preferentially cleaves dsRNAs at their termini without a requirement for ATP*. Embo J, 2002. 21(21): p. 5875-85.
220. Zeng, Y. and Cullen, B.R., *RNA interference in human cells is restricted to the cytoplasm*. Rna, 2002. 8(7): p. 855-60.
221. Hannon, G.J. and Rossi, J.J., *Unlocking the potential of the human genome with RNA interference*. Nature, 2004. 431(7006): p. 371-8.
222. Hannon, G.J., *RNA interference*. Nature, 2002. 418(6894): p. 244-51.
223. Gil, J. and Esteban, M., *Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action*. Apoptosis, 2000. 5(2): p. 107-14.
224. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T., *Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells*. Nature, 2001. 411(6836): p. 494-8.
225. Yu, J.Y., DeRuiter, S.L., and Turner, D.L., *RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells*. Proc Natl Acad Sci U S A, 2002. 99(9): p. 6047-52.
226. Yang, D., Buchholz, F., Huang, Z., Goga, A., Chen, C.Y., Brodsky, F.M., and Bishop, J.M., *Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells*. Proc Natl Acad Sci U S A, 2002. 99(15): p. 9942-7.
227. Baer, M., Nilsen, T.W., Costigan, C., and Altman, S., *Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P*. Nucleic Acids Res, 1990. 18(1): p. 97-103.
228. Brummelkamp, T.R., Bernards, R., and Agami, R., *A system for stable expression of short interfering RNAs in mammalian cells*. Science, 2002. 296(5567): p. 550-3.
229. Sui, G., Soohoo, C., Affar el, B., Gay, F., Shi, Y., Forrester, W.C., and Shi, Y., *A DNA vector-based RNAi technology to suppress gene expression in mammalian cells*. Proc Natl Acad Sci U S A, 2002. 99(8): p. 5515-20.
230. Xia, H., Mao, Q., Paulson, H.L., and Davidson, B.L., *siRNA-mediated gene silencing in vitro and in vivo*. Nat Biotechnol, 2002. 20(10): p. 1006-10.
231. An, D.S., Xie, Y., Mao, S.H., Morizono, K., Kung, S.K., and Chen, I.S., *Efficient lentiviral vectors for short hairpin RNA delivery into human cells*. Hum Gene Ther, 2003. 14(12): p. 1207-12.
232. Barik, S., *Silence of the transcripts: RNA interference in medicine*. J Mol Med, 2005. 83(10): p. 764-73.



233. Lieberman, J., Song, E., Lee, S.K., and Shankar, P., *Interfering with disease: opportunities and roadblocks to harnessing RNA interference*. Trends Mol Med, 2003. 9(9): p. 397-403.
234. Reich, S.J., Fosnot, J., Kuroki, A., Tang, W., Yang, X., Maguire, A.M., Bennett, J., and Tolentino, M.J., *Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model*. Mol Vis, 2003. 9: p. 210-6.
235. Tolentino, M.J., Brucker, A.J., Fosnot, J., Ying, G.S., Wu, I.H., Malik, G., Wan, S., and Reich, S.J., *Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization*. Retina, 2004. 24(1): p. 132-8.
236. Bitko, V., Musiyenko, A., Shulyayeva, O., and Barik, S., *Inhibition of respiratory viruses by nasally administered siRNA*. Nat Med, 2005. 11(1): p. 50-5.
237. Zhang, W., Yang, H., Kong, X., Mohapatra, S., San Juan-Vergara, H., Hellermann, G., Behera, S., Singam, R., Lockey, R.F., and Mohapatra, S.S., *Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene*. Nat Med, 2005. 11(1): p. 56-62.
238. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R.K., Racie, T., Rajeev, K.G., Rohl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Kotliansky, V., Limmer, S., Manoharan, M., and Vornlocher, H.P., *Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs*. Nature, 2004. 432(7014): p. 173-8.
239. Morrissey, D.V., Lockridge, J.A., Shaw, L., Blanchard, K., Jensen, K., Breen, W., Hartsough, K., Machemer, L., Radka, S., Jadhav, V., Vaish, N., Zinnen, S., Vargeese, C., Bowman, K., Shaffer, C.S., Jeffs, L.B., Judge, A., MacLachlan, I., and Polisky, B., *Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs*. Nat Biotechnol, 2005. 23(8): p. 1002-7.
240. Stears, R.L., Martinsky, T., and Schena, M., *Trends in microarray analysis*. Nat Med, 2003. 9(1): p. 140-5.
241. DeRisi, J.L., Iyer, V.R., and Brown, P.O., *Exploring the metabolic and genetic control of gene expression on a genomic scale*. Science, 1997. 278(5338): p. 680-6.
242. Schena, M., Shalon, D., Davis, R.W., and Brown, P.O., *Quantitative monitoring of gene expression patterns with a complementary DNA microarray*. Science, 1995. 270(5235): p. 467-70.
243. Iyer, V.R., Eisen, M.B., Ross, D.T., Schuler, G., Moore, T., Lee, J.C., Trent, J.M., Staudt, L.M., Hudson, J., Jr., Boguski, M.S., Lashkari, D., Shalon, D., Botstein, D., and Brown, P.O., *The transcriptional program in the response of human fibroblasts to serum*. Science, 1999. 283(5398): p. 83-7.
244. Heller, R.A., Schena, M., Chai, A., Shalon, D., Bedilion, T., Gilmore, J., Woolley, D.E., and Davis, R.W., *Discovery and analysis of inflammatory disease-related genes using cDNA microarrays*. Proc Natl Acad Sci U S A, 1997. 94(6): p. 2150-5.
245. Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T.C., Willi, N., Mihatsch, M.J., Sauter, G., and Kallioniemi, O.P., *Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays*. Cancer Res, 1999. 59(4): p. 803-6.
246. Villaret, D.B., Wang, T., Dillon, D., Xu, J., Sivam, D., Cheever, M.A., and Reed, S.G., *Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis*. Laryngoscope, 2000. 110(3 Pt 1): p. 374-81.
247. Whitney, L.W., Becker, K.G., Tresser, N.J., Caballero-Ramos, C.I., Munson, P.J., Prabhu, V.V., Trent, J.M., McFarland, H.F., and Biddison, W.E., *Analysis of gene*

- expression in multiple sclerosis lesions using cDNA microarrays.* Ann Neurol, 1999. 46(3): p. 425-8.
248. Han, J., Yoo, H.Y., Choi, B.H., and Rho, H.M., *Selective transcriptional regulations in the human liver cell by hepatitis B viral X protein.* Biochem Biophys Res Commun, 2000. 272(2): p. 525-30.
249. Hanzel, D.K., Trojanowski, J.Q., Johnston, R.F., and Loring, J.F., *High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner.* Nat Biotechnol, 1999. 17(1): p. 53-7.
250. Hughes, T.R., Marton, M.J., Jones, A.R., Roberts, C.J., Stoughton, R., Armour, C.D., Bennett, H.A., Coffey, E., Dai, H., He, Y.D., Kidd, M.J., King, A.M., Meyer, M.R., Slade, D., Lum, P.Y., Stepaniants, S.B., Shoemaker, D.D., Gachotte, D., Chakraburty, K., Simon, J., Bard, M., and Friend, S.H., *Functional discovery via a compendium of expression profiles.* Cell, 2000. 102(1): p. 109-26.
251. Roth, F.P., Hughes, J.D., Estep, P.W., and Church, G.M., *Finding DNA regulatory motifs within unaligned noncoding sequences clustered by whole-genome mRNA quantitation.* Nat Biotechnol, 1998. 16(10): p. 939-45.
252. Lockhart, D.J. and Winzeler, E.A., *Genomics, gene expression and DNA arrays.* Nature, 2000. 405(6788): p. 827-36.
253. Zhao, B., Bowden, R.A., Stavchansky, S.A., and Bowman, P.D., *Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays.* Am J Physiol Cell Physiol, 2001. 281(5): p. C1587-95.
254. Viemann, D., Goebeler, M., Schmid, S., Klimmek, K., Sorg, C., Ludwig, S., and Roth, J., *Transcriptional profiling of IKK2/NF-kappa B- and p38 MAP kinase-dependent gene expression in TNF-alpha-stimulated primary human endothelial cells.* Blood, 2004. 103(9): p. 3365-73.
255. Franzen, B., Duvefelt, K., Jonsson, C., Engelhardt, B., Ottervald, J., Wickman, M., Yang, Y., and Schuppe-Koistinen, I., *Gene and protein expression profiling of human cerebral endothelial cells activated with tumor necrosis factor-alpha.* Brain Res Mol Brain Res, 2003. 115(2): p. 130-46.
256. Murakami, T., Mataka, C., Nagao, C., Umetani, M., Wada, Y., Ishii, M., Tsutsumi, S., Kohro, T., Saiura, A., Aburatani, H., Hamakubo, T., and Kodama, T., *The gene expression profile of human umbilical vein endothelial cells stimulated by tumor necrosis factor alpha using DNA microarray analysis.* J Atheroscler Thromb, 2000. 7(1): p. 39-44.
257. Zhou, J., Jin, Y., Gao, Y., Wang, H., Hu, G., Huang, Y., Chen, Q., Feng, M., and Wu, C., *Genomic-scale analysis of gene expression profiles in TNF-alpha treated human umbilical vein endothelial cells.* Inflamm Res, 2002. 51(7): p. 332-41.
258. Albrecht, E.A., Chinnaiyan, A.M., Varambally, S., Kumar-Sinha, C., Barrette, T.R., Sarma, J.V., and Ward, P.A., *C5a-induced gene expression in human umbilical vein endothelial cells.* Am J Pathol, 2004. 164(3): p. 849-59.
259. Zhao, B., Stavchansky, S.A., Bowden, R.A., and Bowman, P.D., *Effect of interleukin-1beta and tumor necrosis factor-alpha on gene expression in human endothelial cells.* Am J Physiol Cell Physiol, 2003. 284(6): p. C1577-83.
260. McCormick, S.M., Eskin, S.G., McIntire, L.V., Teng, C.L., Lu, C.M., Russell, C.G., and Chittur, K.K., *DNA microarray reveals changes in gene expression of shear stressed human umbilical vein endothelial cells.* Proc Natl Acad Sci U S A, 2001. 98(16): p. 8955-60.
261. Ohura, N., Yamamoto, K., Ichioka, S., Sokabe, T., Nakatsuka, H., Baba, A., Shibata, M., Nakatsuka, T., Harii, K., Wada, Y., Kohro, T., Kodama, T., and Ando, J., *Global analysis of shear stress-responsive genes in vascular endothelial cells.* J Atheroscler Thromb, 2003. 10(5): p. 304-13.

262. Zhang, S., Day, I.N., and Ye, S., *Microarray analysis of nicotine-induced changes in gene expression in endothelial cells*. *Physiol Genomics*, 2001. 5(4): p. 187-92.
263. Chandrasekharan, U.M., Yang, L., Walters, A., Howe, P., and DiCorleto, P.E., *Role of CL-100, a dual specificity phosphatase, in thrombin-induced endothelial cell activation*. *J Biol Chem*, 2004. 279(45): p. 46678-85.
264. Mayer, H., Bilban, M., Kurtev, V., Gruber, F., Wagner, O., Binder, B.R., and de Martin, R., *Deciphering regulatory patterns of inflammatory gene expression from interleukin-1-stimulated human endothelial cells*. *Arterioscler Thromb Vasc Biol*, 2004. 24(7): p. 1192-8.
265. Pfaffl, M.W., *A new mathematical model for relative quantification in real-time RT-PCR*. *Nucleic Acids Res*, 2001. 29(9): p. e45.
266. Pfaffl, M.W., Horgan, G.W., and Dempfle, L., *Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR*. *Nucleic Acids Res*, 2002. 30(9): p. e36.
267. Wiznerowicz, M. and Trono, D., *Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference*. *J Virol*, 2003. 77(16): p. 8957-61.
268. Graham, F.L. and van der Eb, A.J., *A new technique for the assay of infectivity of human adenovirus 5 DNA*. *Virology*, 1973. 52(2): p. 456-67.
269. Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., Iacus, S., Irizarry, R., Leisch, F., Li, C., Maechler, M., Rossini, A.J., Sawitzki, G., Smith, C., Smyth, G., Tierney, L., Yang, J.Y., and Zhang, J., *Bioconductor: open software development for computational biology and bioinformatics*. *Genome Biol*, 2004. 5(10): p. R80.
270. Breitkreutz, B.J., Jorgensen, P., Breitkreutz, A., and Tyers, M., *AFM 4.0: a toolbox for DNA microarray analysis*. *Genome Biol*, 2001. 2(8): p. SOFTWARE0001.
271. Saeed, A.I., Sharov, V., White, J., Li, J., Liang, W., Bhagabati, N., Braisted, J., Klapa, M., Currier, T., Thiagarajan, M., Sturn, A., Snuffin, M., Rezantsev, A., Popov, D., Ryltsov, A., Kostukovich, E., Borisovsky, I., Liu, Z., Vinsavich, A., Trush, V., and Quackenbush, J., *TM4: a free, open-source system for microarray data management and analysis*. *Biotechniques*, 2003. 34(2): p. 374-8.
272. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P., *Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles*. *Proc Natl Acad Sci U S A*, 2005. 102(43): p. 15545-50.
273. Boussif, O., Lezoualc'h, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., and Behr, J.P., *A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine*. *Proc Natl Acad Sci U S A*, 1995. 92(16): p. 7297-301.
274. Kichler, A., Leborgne, C., Coeytaux, E., and Danos, O., *Polyethylenimine-mediated gene delivery: a mechanistic study*. *J Gene Med*, 2001. 3(2): p. 135-44.
275. Bandyopadhyay, P., Ma, X., Linehan-Stieers, C., Kren, B.T., and Steer, C.J., *Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides. Targeted delivery of liposomes and polyethyleneimine to the asialoglycoprotein receptor*. *J Biol Chem*, 1999. 274(15): p. 10163-72.
276. Dheur, S. and Saison-Behmoaras, T.E., *Polyethyleneimine-mediated transfection to improve antisense activity of 3'-capped phosphodiester oligonucleotides*. *Methods Enzymol*, 2000. 313: p. 56-73.
277. Dheur, S., Dias, N., van Aerschot, A., Herdewijn, P., Bettinger, T., Remy, J.S., Helene, C., and Saison-Behmoaras, E.T., *Polyethylenimine but not cationic lipid improves*

- antisense activity of 3'-capped phosphodiester oligonucleotides*. Antisense Nucleic Acid Drug Dev, 1999. 9(6): p. 515-25.
278. Benigni, A., Tomasoni, S., Lutz, J., Amuchastegui, S., Capogrossi, M.C., and Remuzzi, G., *Nonviral and viral gene transfer to the kidney in the context of transplantation*. Nephron, 2000. 85(4): p. 307-16.
279. Weiss, C., Passow, H., and Rothstein, A., *Autoregulation of flow in isolated rat kidney in the absence of red cells*. Am J Physiol, 1959. 196(5): p. 1115-8.
280. Herrero, I., Torras, J., Carrera, M., Castells, A., Pasto, L., Gil-Vernet, S., Alsina, J., and Grinyo, J.M., *Evaluation of a preservation solution containing fructose-1,6-diphosphate and mannitol using the isolated perfused rat kidney. Comparison with Euro-Collins and University of Wisconsin solutions*. Nephrol Dial Transplant, 1995. 10(4): p. 519-26.
281. Mir, L.M., Bureau, M.F., Gehl, J., Rangara, R., Rouy, D., Caillaud, J.M., Delaere, P., Branellec, D., Schwartz, B., and Scherman, D., *High-efficiency gene transfer into skeletal muscle mediated by electric pulses*. Proc Natl Acad Sci U S A, 1999. 96(8): p. 4262-7.
282. Bettan, M., Emmanuel, F., Darteil, R., Caillaud, J.M., Soubrier, F., Delaere, P., Branellec, D., Mahfoudi, A., Duverger, N., and Scherman, D., *High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle*. Mol Ther, 2000. 2(3): p. 204-10.
283. Lonnstedt, I. and Speed, T.P., *Replicated microarray data*. Stat Sinica, 2002. 12: p. 31-46.
284. Soukas, A., Cohen, P., Socci, N.D., and Friedman, J.M., *Leptin-specific patterns of gene expression in white adipose tissue*. Genes Dev, 2000. 14(8): p. 963-80.
285. Yeung, K.Y., Haynor, D.R., and Ruzzo, W.L., *Validating clustering for gene expression data*. Bioinformatics, 2001. 17(4): p. 309-18.
286. Bonferroni, C.E., *Teoria statistica delle classi e calcolo delle probabilità*. Pubblicazioni del R. Istituto Superiore di Scienze Economiche e Commerciali di Firenze, 1936. 8: p. 3-62.
287. Tusher, V.G., Tibshirani, R., and Chu, G., *Significance analysis of microarrays applied to the ionizing radiation response*. Proc Natl Acad Sci U S A, 2001. 98(9): p. 5116-21.
288. Benjamini, Y. and Hochberg, Y., *Controlling the false discovery rate: A practical and powerful approach to multiple testing*. JRSS-B, 1995. 57: p. 289-300.
289. Kishimoto, T., Taga, T., and Akira, S., *Cytokine signal transduction*. Cell, 1994. 76(2): p. 253-62.
290. Takeda, K., Kaisho, T., and Akira, S., *Toll-like receptors*. Annu Rev Immunol, 2003. 21: p. 335-76.
291. Janeway, C.A., Jr. and Medzhitov, R., *Innate immune recognition*. Annu Rev Immunol, 2002. 20: p. 197-216.
292. Hoffmann, J.A. and Reichhart, J.M., *Drosophila innate immunity: an evolutionary perspective*. Nat Immunol, 2002. 3(2): p. 121-6.
293. Roach, J.C., Glusman, G., Rowen, L., Kaur, A., Purcell, M.K., Smith, K.D., Hood, L.E., and Aderem, A., *The evolution of vertebrate Toll-like receptors*. Proc Natl Acad Sci U S A, 2005. 102(27): p. 9577-82.
294. Alexopoulou, L., Holt, A.C., Medzhitov, R., and Flavell, R.A., *Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3*. Nature, 2001. 413(6857): p. 732-8.
295. Tissari, J., Siren, J., Meri, S., Julkunen, I., and Matikainen, S., *IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression*. J Immunol, 2005. 174(7): p. 4289-94.
296. Faure, E., Equils, O., Sieling, P.A., Thomas, L., Zhang, F.X., Kirschning, C.J., Polentarutti, N., Muzio, M., and Arditi, M., *Bacterial lipopolysaccharide activates NF-*

- kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells.* J Biol Chem, 2000. 275(15): p. 11058-63.
297. Maaser, C., Heidemann, J., von Eiff, C., Luger, A., Spahn, T.W., Binion, D.G., Domschke, W., Luger, N., and Kucharzik, T., *Human intestinal microvascular endothelial cells express Toll-like receptor 5: a binding partner for bacterial flagellin.* J Immunol, 2004. 172(8): p. 5056-62.
298. Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M.X., Kawamata, Y., Fukusumi, S., Hinuma, S., Kitada, C., Kurokawa, T., Onda, H., and Fujino, M., *Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.* Biochem Biophys Res Commun, 1998. 251(2): p. 471-6.
299. Lee, D.K., Cheng, R., Nguyen, T., Fan, T., Kariyawasam, A.P., Liu, Y., Osmond, D.H., George, S.R., and O'Dowd, B.F., *Characterization of apelin, the ligand for the APJ receptor.* J Neurochem, 2000. 74(1): p. 34-41.
300. Ishida, J., Hashimoto, T., Hashimoto, Y., Nishiwaki, S., Iguchi, T., Harada, S., Sugaya, T., Matsuzaki, H., Yamamoto, R., Shiota, N., Okunishi, H., Kihara, M., Umemura, S., Sugiyama, F., Yagami, K., Kasuya, Y., Mochizuki, N., and Fukamizu, A., *Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo.* J Biol Chem, 2004. 279(25): p. 26274-9.
301. Ashley, E.A., Powers, J., Chen, M., Kundu, R., Finsterbach, T., Caffarelli, A., Deng, A., Eichhorn, J., Mahajan, R., Agrawal, R., Greve, J., Robbins, R., Patterson, A.J., Bernstein, D., and Quertermous, T., *The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.* Cardiovasc Res, 2005. 65(1): p. 73-82.
302. Taheri, S., Murphy, K., Cohen, M., Sujkovic, E., Kennedy, A., Dhillon, W., Dakin, C., Sajedi, A., Ghatei, M., and Bloom, S., *The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats.* Biochem Biophys Res Commun, 2002. 291(5): p. 1208-12.
303. Kasai, A., Shintani, N., Oda, M., Kakuda, M., Hashimoto, H., Matsuda, T., Hinuma, S., and Baba, A., *Apelin is a novel angiogenic factor in retinal endothelial cells.* Biochem Biophys Res Commun, 2004. 325(2): p. 395-400.
304. Szokodi, I., Tavi, P., Foldes, G., Voutilainen-Myllyla, S., Ilves, M., Tokola, H., Pikkarainen, S., Piuholta, J., Rysa, J., Toth, M., and Ruskoaho, H., *Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility.* Circ Res, 2002. 91(5): p. 434-40.
305. Jia, Y.X., Pan, C.S., Zhang, J., Geng, B., Zhao, J., Gerns, H., Yang, J., Chang, J.K., Tang, C.S., and Qi, Y.F., *Apelin protects myocardial injury induced by isoproterenol in rats.* Regul Pept, 2006. 133(1-3): p. 147-54.
306. Tatemoto, K., Takayama, K., Zou, M.X., Kumaki, I., Zhang, W., Kumano, K., and Fujimiya, M., *The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism.* Regul Pept, 2001. 99(2-3): p. 87-92.
307. Kanwar, Y.S., Liu, Z.Z., Kashihara, N., and Wallner, E.I., *Current status of the structural and functional basis of glomerular filtration and proteinuria.* Semin Nephrol, 1991. 11(4): p. 390-413.
308. Foglieni, C., Bragonzi, A., Cortese, M., Cantu, L., Boletta, A., Chiossone, I., Soria, M.R., and Monaco, L., *Glomerular filtration is required for transfection of proximal tubular cells in the rat kidney following injection of DNA complexes into the renal artery.* Gene Ther, 2000. 7(4): p. 279-85.
309. Herrero-Fresneda, I., Franquesa, M., Torras, J., Vidal, A., Aran, J., Pluvinet, R., Lloberas, N., Rama, I., Cruzado, J.M., Gulias, O., and Grinyo, J.M., *Role of cold*

- ischemia in acute rejection: characterization of a humoral-like acute rejection in experimental renal transplantation.* Transplant Proc, 2005. 37(9): p. 3712-5.
310. Celotto, A.M. and Graveley, B.R., *Exon-specific RNAi: a tool for dissecting the functional relevance of alternative splicing.* Rna, 2002. 8(6): p. 718-24.
311. Kretschmer-Kazemi Far, R. and Sczakiel, G., *The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides.* Nucleic Acids Res, 2003. 31(15): p. 4417-24.
312. Bertrand, J.R., Pottier, M., Vekris, A., Opolon, P., Maksimenko, A., and Malvy, C., *Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.* Biochem Biophys Res Commun, 2002. 296(4): p. 1000-4.
313. Paul, C.P., Good, P.D., Winer, I., and Engelke, D.R., *Effective expression of small interfering RNA in human cells.* Nat Biotechnol, 2002. 20(5): p. 505-8.
314. Scherer, L. and Rossi, J.J., *Therapeutic applications of RNA interference: recent advances in siRNA design.* Adv Genet, 2004. 52: p. 1-21.
315. Jackson, A.L. and Linsley, P.S., *Noise amidst the silence: off-target effects of siRNAs?* Trends Genet, 2004. 20(11): p. 521-4.
316. Sledz, C.A., Holko, M., de Veer, M.J., Silverman, R.H., and Williams, B.R., *Activation of the interferon system by short-interfering RNAs.* Nat Cell Biol, 2003. 5(9): p. 834-9.
317. Bantounas, I., Phylactou, L.A., and Uney, J.B., *RNA interference and the use of small interfering RNA to study gene function in mammalian systems.* J Mol Endocrinol, 2004. 33(3): p. 545-57.
318. Thomas, C.E., Ehrhardt, A., and Kay, M.A., *Progress and problems with the use of viral vectors for gene therapy.* Nat Rev Genet, 2003. 4(5): p. 346-58.
319. Dadgostar, H., Zarnegar, B., Hoffmann, A., Qin, X.F., Truong, U., Rao, G., Baltimore, D., and Cheng, G., *Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes.* Proc Natl Acad Sci U S A, 2002. 99(3): p. 1497-502.
320. Gricks, C.S., Zahrieh, D., Zauls, A.J., Gorgun, G., Drandi, D., Mauerer, K., Neuberg, D., and Gribben, J.G., *Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells.* Blood, 2004. 104(13): p. 4002-9.
321. Phipps, R.P., *Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system.* Proc Natl Acad Sci U S A, 2000. 97(13): p. 6930-2.
322. Siwkowski, A.M., Madge, L.A., Koo, S., McMillan, E.L., Monia, B.P., Pober, J.S., and Baker, B.F., *Effects of antisense oligonucleotide-mediated depletion of tumor necrosis factor (TNF) receptor 1-associated death domain protein on TNF-induced gene expression.* Mol Pharmacol, 2004. 66(3): p. 572-9.
323. Hesser, B.A., Liang, X.H., Camenisch, G., Yang, S., Lewin, D.A., Scheller, R., Ferrara, N., and Gerber, H.P., *Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells.* Blood, 2004. 104(1): p. 149-58.
324. Carballo, E., Lai, W.S., and Blakeshear, P.J., *Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin.* Science, 1998. 281(5379): p. 1001-5.
325. Carballo, E., Lai, W.S., and Blakeshear, P.J., *Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability.* Blood, 2000. 95(6): p. 1891-9.
326. Mann, J., Oakley, F., Johnson, P.W., and Mann, D.A., *CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-kappa B, AND CBF1.* J Biol Chem, 2002. 277(19): p. 17125-38.
327. Baccam, M., Woo, S.Y., Vinson, C., and Bishop, G.A., *CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-kappa B, AP-1, and C/EBP.* J Immunol, 2003. 170(6): p. 3099-108.

328. Bavendiek, U., Libby, P., Kilbride, M., Reynolds, R., Mackman, N., and Schonbeck, U., *Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1*. J Biol Chem, 2002. 277(28): p. 25032-9.
329. Rouyez, M.C., Lestingi, M., Charon, M., Fichelson, S., Buzyn, A., and Dusanter-Fourt, I., *IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity*. J Immunol, 2005. 174(7): p. 3948-58.
330. Warton, K., Foster, N.C., Gold, W.A., and Stanley, K.K., *A novel gene family induced by acute inflammation in endothelial cells*. Gene, 2004. 342(1): p. 85-95.
331. Pluvinet, R., Petriz, J., Torras, J., Herrero-Fresneda, I., Cruzado, J.M., Grinyo, J.M., and Aran, J.M., *RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells*. Blood, 2004. 104(12): p. 3642-6.
332. Henn, V., Slupsky, J.R., Grafe, M., Anagnostopoulos, I., Forster, R., Muller-Berghaus, G., and Kroczek, R.A., *CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells*. Nature, 1998. 391(6667): p. 591-4.
333. Takahashi, M., Kitagawa, S., Masuyama, J.I., Ikeda, U., Kasahara, T., Takahashi, Y.I., Furukawa, Y., Kano, S., and Shimada, K., *Human monocyte-endothelial cell interaction induces synthesis of granulocyte-macrophage colony-stimulating factor*. Circulation, 1996. 93(6): p. 1185-93.
334. Dechanet, J., Grosset, C., Taupin, J.L., Merville, P., Banchereau, J., Ripoche, J., and Moreau, J.F., *CD40 ligand stimulates proinflammatory cytokine production by human endothelial cells*. J Immunol, 1997. 159(11): p. 5640-7.
335. Omari, K.M., Chui, R., and Dorovini-Zis, K., *Induction of beta-chemokine secretion by human brain microvessel endothelial cells via CD40/CD40L interactions*. J Neuroimmunol, 2004. 146(1-2): p. 203-8.
336. Testi, R., D'Ambrosio, D., De Maria, R., and Santoni, A., *The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells*. Immunol Today, 1994. 15(10): p. 479-83.
337. Laffon, A., Garcia-Vicuna, R., Humbria, A., Postigo, A.A., Corbi, A.L., de Landazuri, M.O., and Sanchez-Madrid, F., *Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis*. J Clin Invest, 1991. 88(2): p. 546-52.
338. Kitada, S., Zapata, J.M., Andreeff, M., and Reed, J.C., *Bryostatins and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia*. Br J Haematol, 1999. 106(4): p. 995-1004.
339. Bates, E.E., Ravel, O., Dieu, M.C., Ho, S., Guret, C., Bridon, J.M., Ait-Yahia, S., Briere, F., Caux, C., Banchereau, J., and Lebecque, S., *Identification and analysis of a novel member of the ubiquitin family expressed in dendritic cells and mature B cells*. Eur J Immunol, 1997. 27(10): p. 2471-7.
340. Raasi, S., Schmidtke, G., de Giuli, R., and Groettrup, M., *A ubiquitin-like protein which is synergistically inducible by interferon-gamma and tumor necrosis factor-alpha*. Eur J Immunol, 1999. 29(12): p. 4030-6.
341. Hipp, M.S., Kalveram, B., Raasi, S., Groettrup, M., and Schmidtke, G., *FAT10, a ubiquitin-independent signal for proteasomal degradation*. Mol Cell Biol, 2005. 25(9): p. 3483-91.
342. Higashitsuji, H., Liu, Y., Mayer, R.J., and Fujita, J., *The oncoprotein gankyrin negatively regulates both p53 and RB by enhancing proteasomal degradation*. Cell Cycle, 2005. 4(10): p. 1335-7.
343. Khanna, R., Cooper, L., Kienzle, N., Moss, D.J., Burrows, S.R., and Khanna, K.K., *Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide*

- transporter expression and restores endogenous processing function in Burkitt's lymphoma cells.* J Immunol, 1997. 159(12): p. 5782-5.
344. Blom, A.M., Kask, L., and Dahlback, B., *CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b.* Mol Immunol, 2003. 39(10): p. 547-56.
345. Kusada-Funakoshi, M., Sasaki, J., Takada, Y., Soji, T., and Arakawa, K., *Evidence that C4b-binding protein (proline-rich protein) is synthesized by hepatocytes.* Biochem Med Metab Biol, 1991. 45(3): p. 350-4.
346. Brodeur, S.R., Angelini, F., Bacharier, L.B., Blom, A.M., Mizoguchi, E., Fujiwara, H., Plebani, A., Notarangelo, L.D., Dahlback, B., Tsitsikov, E., and Geha, R.S., *C4b-binding protein (C4BP) activates B cells through the CD40 receptor.* Immunity, 2003. 18(6): p. 837-48.
347. Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M., and Goeddel, D.V., *The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins.* Cell, 1995. 83(7): p. 1243-52.
348. Craxton, A., Shu, G., Graves, J.D., Saklatvala, J., Krebs, E.G., and Clark, E.A., *p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes.* J Immunol, 1998. 161(7): p. 3225-36.
349. Deveraux, Q.L., Takahashi, R., Salvesen, G.S., and Reed, J.C., *X-linked IAP is a direct inhibitor of cell-death proteases.* Nature, 1997. 388(6639): p. 300-4.
350. Stehlik, C., de Martin, R., Kumabashiri, I., Schmid, J.A., Binder, B.R., and Lipp, J., *Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis.* J Exp Med, 1998. 188(1): p. 211-6.
351. Ferran, C., Stroka, D.M., Badrichani, A.Z., Cooper, J.T., Wrighton, C.J., Soares, M., Grey, S.T., and Bach, F.H., *A20 inhibits NF-kappaB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis.* Blood, 1998. 91(7): p. 2249-58.
352. Deregibus, M.C., Buttiglieri, S., Russo, S., Bussolati, B., and Camussi, G., *CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis.* J Biol Chem, 2003. 278(20): p. 18008-14.
353. Krucken, J., Epe, M., Benten, W.P., Falkenroth, N., and Wunderlich, F., *Malaria-suppressible expression of the anti-apoptotic triple GTPase mGIMAP8.* J Cell Biochem, 2005. 96(2): p. 339-48.
354. Dallman, C., Johnson, P.W., and Packham, G., *Differential regulation of cell survival by CD40.* Apoptosis, 2003. 8(1): p. 45-53.
355. Craxton, A., Chuang, P.I., Shu, G., Harlan, J.M., and Clark, E.A., *The CD40-inducible Bcl-2 family member A1 protects B cells from antigen receptor-mediated apoptosis.* Cell Immunol, 2000. 200(1): p. 56-62.
356. Ishida, T., Kobayashi, N., Tojo, T., Ishida, S., Yamamoto, T., and Inoue, J., *CD40 signaling-mediated induction of Bcl-XL, Cdk4, and Cdk6. Implication of their cooperation in selective B cell growth.* J Immunol, 1995. 155(12): p. 5527-35.
357. Hirai, H., Adachi, T., and Tsubata, T., *Involvement of cell cycle progression in survival signaling through CD40 in the B-lymphocyte line WEHI-231.* Cell Death Differ, 2004. 11(3): p. 261-9.
358. Olson, N.E., Graves, J.D., Shu, G.L., Ryan, E.J., and Clark, E.A., *Caspase activity is required for stimulated B lymphocytes to enter the cell cycle.* J Immunol, 2003. 170(12): p. 6065-72.
359. Xia, C., Bao, Z., Tabassam, F., Ma, W., Qiu, M., Hua, S., and Liu, M., *GCIP, a novel human grap2 and cyclin D interacting protein, regulates E2F-mediated transcriptional activity.* J Biol Chem, 2000. 275(27): p. 20942-8.



360. Janumyan, Y.M., Sansam, C.G., Chattopadhyay, A., Cheng, N., Soucie, E.L., Penn, L.Z., Andrews, D., Knudson, C.M., and Yang, E., *Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry*. *Embo J*, 2003. 22(20): p. 5459-70.
361. Poe, J.C., Haas, K.M., Uchida, J., Lee, Y., Fujimoto, M., and Tedder, T.F., *Severely impaired B lymphocyte proliferation, survival, and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background*. *J Immunol*, 2004. 172(4): p. 2100-10.
362. Schonbeck, U., Mach, F., Bonnefoy, J.Y., Loppnow, H., Flad, H.D., and Libby, P., *Ligation of CD40 activates interleukin 1beta-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1beta*. *J Biol Chem*, 1997. 272(31): p. 19569-74.
363. Fantuzzi, G. and Dinarello, C.A., *Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1)*. *J Clin Immunol*, 1999. 19(1): p. 1-11.
364. Cookson, B.T. and Brennan, M.A., *Pro-inflammatory programmed cell death*. *Trends Microbiol*, 2001. 9(3): p. 113-4.
365. Inoue, Y., Otsuka, T., Niuro, H., Nagano, S., Arinobu, Y., Ogami, E., Akahoshi, M., Miyake, K., Ninomiya, I., Shimizu, S., Nakashima, H., and Harada, M., *Novel regulatory mechanisms of CD40-induced prostanoid synthesis by IL-4 and IL-10 in human monocytes*. *J Immunol*, 2004. 172(4): p. 2147-54.
366. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and Santoro, M.G., *Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkkappaB kinase*. *Nature*, 2000. 403(6765): p. 103-8.
367. Horrevoets, A.J., Fontijn, R.D., van Zonneveld, A.J., de Vries, C.J., ten Cate, J.W., and Pannekoek, H., *Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes*. *Blood*, 1999. 93(10): p. 3418-31.
368. Ogg, S.L., Weldon, A.K., Dobbie, L., Smith, A.J., and Mather, I.H., *Expression of butyrophilin (Bt1a1) in lactating mammary gland is essential for the regulated secretion of milk-lipid droplets*. *Proc Natl Acad Sci U S A*, 2004. 101(27): p. 10084-9.
369. Melter, M., Reinders, M.E., Sho, M., Pal, S., Geehan, C., Denton, M.D., Mukhopadhyay, D., and Briscoe, D.M., *Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo*. *Blood*, 2000. 96(12): p. 3801-8.
370. Reinders, M.E., Sho, M., Izawa, A., Wang, P., Mukhopadhyay, D., Koss, K.E., Geehan, C.S., Luster, A.D., Sayegh, M.H., and Briscoe, D.M., *Proinflammatory functions of vascular endothelial growth factor in alloimmunity*. *J Clin Invest*, 2003. 112(11): p. 1655-65.
371. Ferrara, N., Gerber, H.P., and LeCouter, J., *The biology of VEGF and its receptors*. *Nat Med*, 2003. 9(6): p. 669-76.
372. Mach, F., Schonbeck, U., Fabunmi, R.P., Murphy, C., Atkinson, E., Bonnefoy, J.Y., Graber, P., and Libby, P., *T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation*. *Am J Pathol*, 1999. 154(1): p. 229-38.
373. Reinders, M.E., Sho, M., Robertson, S.W., Geehan, C.S., and Briscoe, D.M., *Proangiogenic function of CD40 ligand-CD40 interactions*. *J Immunol*, 2003. 171(3): p. 1534-41.
374. Chakraborti, S., Mandal, M., Das, S., Mandal, A., and Chakraborti, T., *Regulation of matrix metalloproteinases: an overview*. *Mol Cell Biochem*, 2003. 253(1-2): p. 269-85.
375. Saunders, W.B., Bayless, K.J., and Davis, G.E., *MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices*. *J Cell Sci*, 2005. 118(Pt 10): p. 2325-40.

376. Chang, S., Young, B.D., Li, S., Qi, X., Richardson, J.A., and Olson, E.N., *Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10*. *Cell*, 2006. 126(2): p. 321-34.
377. Spinale, F.G., *Matrix metalloproteinases: regulation and dysregulation in the failing heart*. *Circ Res*, 2002. 90(5): p. 520-30.
378. Miller, D.L., Yaron, R., and Yellin, M.J., *CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression*. *J Leukoc Biol*, 1998. 63(3): p. 373-9.
379. Myles, T., Nishimura, T., Yun, T.H., Nagashima, M., Morser, J., Patterson, A.J., Pearl, R.G., and Leung, L.L., *Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation*. *J Biol Chem*, 2003. 278(51): p. 51059-67.
380. O'Dowd, B.F., Heiber, M., Chan, A., Heng, H.H., Tsui, L.C., Kennedy, J.L., Shi, X., Petronis, A., George, S.R., and Nguyen, T., *A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11*. *Gene*, 1993. 136(1-2): p. 355-60.
381. Garden, R.W., Moroz, T.P., Gleeson, J.M., Floyd, P.D., Li, L., Rubakhin, S.S., and Sweedler, J.V., *Formation of N-pyroglutamyl peptides from N-Glu and N-Gln precursors in Aplysia neurons*. *J Neurochem*, 1999. 72(2): p. 676-81.
382. Habata, Y., Fujii, R., Hosoya, M., Fukusumi, S., Kawamata, Y., Hinuma, S., Kitada, C., Nishizawa, N., Murotsuki, S., Kurokawa, T., Onda, H., Tatemoto, K., and Fujino, M., *Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum*. *Biochim Biophys Acta*, 1999. 1452(1): p. 25-35.
383. Beltowski, J., *Apelin and visfatin: Unique "beneficial" adipokines upregulated in obesity?* *Med Sci Monit*, 2006. 12(6): p. RA112-119.
384. Kleinz, M.J. and Davenport, A.P., *Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells*. *Regul Pept*, 2004. 118(3): p. 119-25.
385. Kleinz, M.J., Skepper, J.N., and Davenport, A.P., *Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells*. *Regul Pept*, 2005. 126(3): p. 233-40.
386. Sorli, S.C., van den Berghe, L., Masri, B., Knibiehler, B., and Audigier, Y., *Therapeutic potential of interfering with apelin signalling*. *Drug Discov Today*, 2006. 11(23-24): p. 1100-6.
387. Masri, B., Morin, N., Cornu, M., Knibiehler, B., and Audigier, Y., *Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells*. *Faseb J*, 2004. 18(15): p. 1909-11.
388. Daviaud, D., Boucher, J., Gesta, S., Dray, C., Guigne, C., Quilliot, D., Ayav, A., Ziegler, O., Carpenne, C., Saulnier-Blache, J.S., Valet, P., and Castan-Laurell, I., *TNFalpha up-regulates apelin expression in human and mouse adipose tissue*. *Faseb J*, 2006. 20(9): p. 1528-30.
389. Medhurst, A.D., Jennings, C.A., Robbins, M.J., Davis, R.P., Ellis, C., Winborn, K.Y., Lawrie, K.W., Hervieu, G., Riley, G., Bolaky, J.E., Herrity, N.C., Murdock, P., and Darker, J.G., *Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin*. *J Neurochem*, 2003. 84(5): p. 1162-72.
390. Kawamata, Y., Habata, Y., Fukusumi, S., Hosoya, M., Fujii, R., Hinuma, S., Nishizawa, N., Kitada, C., Onda, H., Nishimura, O., and Fujino, M., *Molecular properties of apelin: tissue distribution and receptor binding*. *Biochim Biophys Acta*, 2001. 1538(2-3): p. 162-71.
391. Katugampola, S.D., Maguire, J.J., Matthewson, S.R., and Davenport, A.P., *[(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in*

- human and rat tissues with evidence for a vasoconstrictor role in man. *Br J Pharmacol*, 2001. 132(6): p. 1255-60.
392. Cohen, R.A. and Vanhoutte, P.M., *Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP*. *Circulation*, 1995. 92(11): p. 3337-49.
393. Davenport, A.P., Nunez, D.J., Hall, J.A., Kaumann, A.J., and Brown, M.J., *Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans*. *J Cardiovasc Pharmacol*, 1989. 13 Suppl 5: p. S166-70.
394. Foldes, G., Horkay, F., Szokodi, I., Vuolteenaho, O., Ilves, M., Lindstedt, K.A., Mayranpaa, M., Sarman, B., Seres, L., Skoumal, R., Lako-Futo, Z., deChatel, R., Ruskoaho, H., and Toth, M., *Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure*. *Biochem Biophys Res Commun*, 2003. 308(3): p. 480-5.
395. Chen, M.M., Ashley, E.A., Deng, D.X., Tsalenko, A., Deng, A., Tabibiazar, R., Bendor, A., Fenster, B., Yang, E., King, J.Y., Fowler, M., Robbins, R., Johnson, F.L., Bruhn, L., McDonagh, T., Dargie, H., Yakhini, Z., Tsao, P.S., and Quertermous, T., *Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction*. *Circulation*, 2003. 108(12): p. 1432-9.
396. Wang, G., Qi, X., Wei, W., Englander, E.W., and Greeley, G.H., Jr., *Characterization of the 5'-regulatory regions of the rat and human apelin genes and regulation of breast apelin by USF*. *Faseb J*, 2006. 20(14): p. 2639-41.
397. Shaulian, E. and Karin, M., *AP-1 as a regulator of cell life and death*. *Nat Cell Biol*, 2002. 4(5): p. E131-6.
398. Sassone-Corsi, P. and Verma, I.M., *Modulation of c-fos gene transcription by negative and positive cellular factors*. *Nature*, 1987. 326(6112): p. 507-10.
399. Wisdom, R., *AP-1: one switch for many signals*. *Exp Cell Res*, 1999. 253(1): p. 180-5.
400. Wang, N., Verna, L., Liao, H., Ballard, A., Zhu, Y., and Stemerman, M.B., *Adenovirus-mediated overexpression of dominant-negative mutant of c-Jun prevents intercellular adhesion molecule-1 induction by LDL: a critical role for activator protein-1 in endothelial activation*. *Arterioscler Thromb Vasc Biol*, 2001. 21(9): p. 1414-20.
401. Karin, M., *The regulation of AP-1 activity by mitogen-activated protein kinases*. *J Biol Chem*, 1995. 270(28): p. 16483-6.
402. Angel, P. and Karin, M., *The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation*. *Biochim Biophys Acta*, 1991. 1072(2-3): p. 129-57.
403. Yasumoto, K., Okamoto, S., Mukaida, N., Murakami, S., Mai, M., and Matsushima, K., *Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene*. *J Biol Chem*, 1992. 267(31): p. 22506-11.
404. Stein, B., Baldwin, A.S., Jr., Ballard, D.W., Greene, W.C., Angel, P., and Herrlich, P., *Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function*. *Embo J*, 1993. 12(10): p. 3879-91.
405. Yang, S.H., Whitmarsh, A.J., Davis, R.J., and Sharrocks, A.D., *Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1*. *Embo J*, 1998. 17(6): p. 1740-9.
406. Ramsauer, K., Sadzak, I., Porras, A., Pilz, A., Nebreda, A.R., Decker, T., and Kovarik, P., *p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation*. *Proc Natl Acad Sci U S A*, 2002. 99(20): p. 12859-64.
407. Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K., and Cobb, M.H., *Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions*. *Endocr Rev*, 2001. 22(2): p. 153-83.

408. Sano, Y., Harada, J., Tashiro, S., Gotoh-Mandeville, R., Maekawa, T., and Ishii, S., *ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling*. J Biol Chem, 1999. 274(13): p. 8949-57.
409. Min, W. and Pober, J.S., *TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-kappa B and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways*. J Immunol, 1997. 159(7): p. 3508-18.
410. Goebeler, M., Kilian, K., Gillitzer, R., Kunz, M., Yoshimura, T., Brocker, E.B., Rapp, U.R., and Ludwig, S., *The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-alpha-induced expression of monocyte-chemoattractant protein-1 in endothelial cells*. Blood, 1999. 93(3): p. 857-65.
411. Han, Z., Boyle, D.L., Chang, L., Bennett, B., Karin, M., Yang, L., Manning, A.M., and Firestein, G.S., *c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis*. J Clin Invest, 2001. 108(1): p. 73-81.
412. Lewis, T.S., Shapiro, P.S., and Ahn, N.G., *Signal transduction through MAP kinase cascades*. Adv Cancer Res, 1998. 74: p. 49-139.
413. Cavigelli, M., Dolfi, F., Claret, F.X., and Karin, M., *Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation*. Embo J, 1995. 14(23): p. 5957-64.
414. Wang, Y. and Prywes, R., *Activation of the c-fos enhancer by the erk MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites*. Oncogene, 2000. 19(11): p. 1379-85.
415. Dumitru, C.D., Ceci, J.D., Tsatsanis, C., Kontoyiannis, D., Stamatakis, K., Lin, J.H., Patriotis, C., Jenkins, N.A., Copeland, N.G., Kollias, G., and Tschlis, P.N., *TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway*. Cell, 2000. 103(7): p. 1071-83.
416. Slack, J.L., Schooley, K., Bonnert, T.P., Mitcham, J.L., Qwarnstrom, E.E., Sims, J.E., and Dower, S.K., *Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways*. J Biol Chem, 2000. 275(7): p. 4670-8.
417. Li, K., Chen, Z., Kato, N., Gale, M., Jr., and Lemon, S.M., *Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes*. J Biol Chem, 2005. 280(17): p. 16739-47.
418. Le Bon, A. and Tough, D.F., *Links between innate and adaptive immunity via type I interferon*. Curr Opin Immunol, 2002. 14(4): p. 432-6.
419. Poeck, H., Wagner, M., Battiany, J., Rothenfusser, S., Wellisch, D., Hornung, V., Jahrsdorfer, B., Giese, T., Endres, S., and Hartmann, G., *Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help*. Blood, 2004. 103(8): p. 3058-64.
420. Banchereau, J., Pascual, V., and Palucka, A.K., *Autoimmunity through cytokine-induced dendritic cell activation*. Immunity, 2004. 20(5): p. 539-50.
421. Jego, G., Palucka, A.K., Blanck, J.P., Chalouni, C., Pascual, V., and Banchereau, J., *Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6*. Immunity, 2003. 19(2): p. 225-34.
422. Braun, D., Caramalho, I., and Demengeot, J., *IFN-alpha/beta enhances BCR-dependent B cell responses*. Int Immunol, 2002. 14(4): p. 411-9.
423. Andreakos, E., Foxwell, B., and Feldmann, M., *Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?* Immunol Rev, 2004. 202: p. 250-65.
424. Luft, T., Maraskovsky, E., Schnurr, M., Knebel, K., Kirsch, M., Gorner, M., Skoda, R., Ho, A.D., Nawroth, P., and Bierhaus, A., *Tuning the volume of the immune response:*

- strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells.* Blood, 2004. 104(4): p. 1066-74.
425. Mathur, R.K., Awasthi, A., Wadhone, P., Ramanamurthy, B., and Saha, B., *Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses.* Nat Med, 2004. 10(5): p. 540-4.
426. Bosch, R.J., Woolf, A.S., and Fine, L.G., *Gene transfer into the mammalian kidney: direct retrovirus-transduction of regenerating tubular epithelial cells.* Exp Nephrol, 1993. 1(1): p. 49-54.
427. Heikkila, P., Parpala, T., Lukkarinen, O., Weber, M., and Tryggvason, K., *Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system - first steps towards gene therapy of Alport syndrome.* Gene Ther, 1996. 3(1): p. 21-7.
428. Lai, L.W., Moeckel, G.W., and Lien, Y.H., *Kidney-targeted liposome-mediated gene transfer in mice.* Gene Ther, 1997. 4(5): p. 426-31.
429. Boletta, A., Benigni, A., Lutz, J., Remuzzi, G., Soria, M.R., and Monaco, L., *Nonviral gene delivery to the rat kidney with polyethylenimine.* Hum Gene Ther, 1997. 8(10): p. 1243-51.
430. Kay, M.A., Holterman, A.X., Meuse, L., Gown, A., Ochs, H.D., Linsley, P.S., and Wilson, C.B., *Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration.* Nat Genet, 1995. 11(2): p. 191-7.
431. Akhtar, S. and Agrawal, S., *In vivo studies with antisense oligonucleotides.* Trends Pharmacol Sci, 1997. 18(1): p. 12-8.
432. Akagi, Y., Isaka, Y., Arai, M., Kaneko, T., Takenaka, M., Moriyama, T., Kaneda, Y., Ando, A., Orita, Y., Kamada, T., Ueda, N., and Imai, E., *Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis.* Kidney Int, 1996. 50(1): p. 148-55.
433. Kashihara, N., Maeshima, Y., and Makino, H., *Therapeutic intervention in glomerulonephritis by oligonucleotides.* Exp Nephrol, 1997. 5(2): p. 126-31.
434. Noiri, E., Peresleni, T., Miller, F., and Goligorsky, M.S., *In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia.* J Clin Invest, 1996. 97(10): p. 2377-83.
435. Haller, H., Dragun, D., Miethke, A., Park, J.K., Weis, A., Lippoldt, A., Gross, V., and Luft, F.C., *Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat.* Kidney Int, 1996. 50(2): p. 473-80.
436. Takabatake, Y., Isaka, Y., Mizui, M., Kawachi, H., Shimizu, F., Ito, T., Hori, M., and Imai, E., *Exploring RNA interference as a therapeutic strategy for renal disease.* Gene Ther, 2005. 12(12): p. 965-73.
437. Du, C., Wang, S., Diao, H., Guan, Q., Zhong, R., and Jevnikar, A.M., *Increasing resistance of tubular epithelial cells to apoptosis by shRNA therapy ameliorates renal ischemia-reperfusion injury.* Am J Transplant, 2006. 6(10): p. 2256-67.
438. Zheng, X., Zhang, X., Sun, H., Feng, B., Li, M., Chen, G., Vladau, C., Chen, D., Suzuki, M., Min, L., Liu, W., Zhong, R., Garcia, B., Jevnikar, A., and Min, W.P., *Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes.* Transplantation, 2006. 82(12): p. 1781-6.
439. Chiu, Y.L. and Rana, T.M., *siRNA function in RNAi: a chemical modification analysis.* Rna, 2003. 9(9): p. 1034-48.
440. Aihara, H. and Miyazaki, J., *Gene transfer into muscle by electroporation in vivo.* Nat Biotechnol, 1998. 16(9): p. 867-70.
441. Mathiesen, I., *Electropermeabilization of skeletal muscle enhances gene transfer in vivo.* Gene Ther, 1999. 6(4): p. 508-14.

442. Vicat, J.M., Boisseau, S., Jourdes, P., Laine, M., Wion, D., Bouali-Benazzouz, R., Benabid, A.L., and Berger, F., *Muscle transfection by electroporation with high-voltage and short-pulse currents provides high-level and long-lasting gene expression*. Hum Gene Ther, 2000. 11(6): p. 909-16.
443. Goto, T., Nishi, T., Tamura, T., Dev, S.B., Takeshima, H., Kochi, M., Yoshizato, K., Kuratsu, J., Sakata, T., Hofmann, G.A., and Ushio, Y., *Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene*. Proc Natl Acad Sci U S A, 2000. 97(1): p. 354-9.
444. Titomirov, A.V., Sukharev, S., and Kistanova, E., *In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA*. Biochim Biophys Acta, 1991. 1088(1): p. 131-4.
445. Heller, R., Jaroszeski, M., Atkin, A., Moradpour, D., Gilbert, R., Wands, J., and Nicolau, C., *In vivo gene electroinjection and expression in rat liver*. FEBS Lett, 1996. 389(3): p. 225-8.
446. Muramatsu, T., Shibata, O., Ryoki, S., Ohmori, Y., and Okumura, J., *Foreign gene expression in the mouse testis by localized in vivo gene transfer*. Biochem Biophys Res Commun, 1997. 233(1): p. 45-9.
447. Harrison, R.L., Byrne, B.J., and Tung, L., *Electroporation-mediated gene transfer in cardiac tissue*. FEBS Lett, 1998. 435(1): p. 1-5.